Genetically modified non-human animals possessing a shared light chain immunoglobulin gene locus

By genetically modifying the light chain immunoglobulin locus of non-human animals, humanized antibodies are generated, solving the problem of generating humanized bispecific antibodies in existing technologies, improving binding affinity and biophysical properties, reducing immunogenicity, and simplifying the manufacturing process.

CN115667532BActive Publication Date: 2026-11-10BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202180039972.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-04-07
Filing Date
2021-06-01
Publication Date
2026-11-10
Estimated Expiration
2041-06-01

AI Technical Summary

Technical Problem

Existing technologies struggle to efficiently generate humanized bispecific antibodies, exhibiting issues such as poor binding affinity, poor biophysical properties, and immunogenicity problems. Furthermore, the manufacturing process is complex and time-consuming.

Method used

By genetically modifying non-human animals to include a limited number of human IGKV and IGKJ genes in their endogenous light chain immunoglobulin loci, and combining them with human heavy chain variable domains, diverse light chain variable domain pairings are generated to prepare chimeric antibodies.

Benefits of technology

It achieves efficient generation of humanized antibodies, improves binding affinity and biophysical properties, reduces immunogenicity, and simplifies the manufacturing process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115667532B_ABST
    Figure CN115667532B_ABST
Patent Text Reader

Abstract

A genetically modified animal having a humanized light chain immunoglobulin locus, wherein the endogenous light chain immunoglobulin locus contains a limited number of human IGKV and IGKJ genes; cells obtained from said animal; and a method for exposing said animal to an antigen.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority Statement

[0002] This application claims the benefits of PCT application No. PCT / CN 2020 / 094000, filed on June 2, 2020, and PCT application No. PCT / CN 2021 / 085839, filed on April 7, 2021. The entire foregoing is incorporated herein by reference. Technical Field

[0003] This disclosure relates to genetically modified animals and cells having humanized light chain immunoglobulin loci and / or humanized heavy chain immunoglobulin loci. Background Technology

[0004] Antibodies are immune proteins that bind to specific antigens. Typically, antibodies are target-specific, capable of mediating immune effector mechanisms, and have a long half-life in serum. These properties make antibodies potent therapeutic agents. Monoclonal antibodies are used to treat a variety of conditions, including cancer, infectious diseases, autoimmune diseases, and inflammatory diseases. Many novel antibody forms have been proposed for various therapeutic purposes. For example, bispecific antibodies can bind to two different targets or two different epitopes on a target, producing additive or synergistic effects superior to those of monoclonal antibodies. However, the manufacture of bispecific antibodies is challenging due to mismatch problems.

[0005] Furthermore, these therapeutic antibodies are typically human antibodies or humanized antibodies. Human antibodies or humanized antibodies can be generated through the humanization of rodent antibodies (e.g., mouse antibodies) or by using phage libraries. Antibodies generated by these methods often have suboptimal binding affinity and biophysical properties, leading to manufacturing difficulties and poor pharmacokinetics. In particular, the humanization process can adversely affect binding affinity, introduce immunogenic epitopes into the antibody, and antibodies discovered using phage libraries exhibit limited diversity and non-natural pairings of immunoglobulin heavy and light chains. Iterative and time-consuming experiments are often required to improve the properties. And in some cases, these antibodies can also induce immunogenicity in patients.

[0006] There is a need for efficient and cost-effective methods to generate humanized antibodies, and in particular, a platform for generating humanized bispecific antibodies for a variety of therapeutic purposes. Summary of the Invention

[0007] This disclosure relates to genetically modified animals and cells having humanized heavy and light chain immunoglobulin loci. In some embodiments, the genetically modified animals possess a limited set of human IGKV and IGKJ genes at the endogenous light chain immunoglobulin loci. In one aspect, the genetically modified animals as described herein can generate immunoglobulin light chain variable domains that can pair with a fairly diverse family of heavy chain variable domains, including, for example, affinity-matured or somatically mutated variable domains.

[0008] In one aspect, this disclosure provides genetically modified non-human animals that contain exogenous light chain variable region gene sequences at endogenous light chain immunoglobulin loci. In some embodiments, the exogenous light chain variable region gene sequence comprises no more than three human IGKV genes and no more than two human IGKJ genes. In some embodiments, the no more than three human IGKV genes and the no more than two human IGKJ genes are operatively linked to endogenous light chain constant domain genes.

[0009] In some implementations, the IGKV genes of no more than three individuals are selected from Table 1, and the IGKJ genes of no more than two individuals are selected from Table 2.

[0010] In some embodiments, the exogenous light chain variable region gene sequence comprises a human IGKV gene and a human IGKJ gene.

[0011] In some embodiments, the exogenous light chain variable region gene sequence further comprises a human IGKJ 3'-UTR sequence. In some embodiments, the exogenous light chain variable region gene sequence in one or more cells of the animal may undergo somatic hypermutation.

[0012] In some embodiments, the somatic hypermutation can result in a change of up to one, two, or three amino acids in the light chain variable region of one or more cells of the animal.

[0013] In some embodiments, the exogenous light chain variable region gene sequence comprises a human IGKV gene and a human IGKJ gene. In some embodiments, the human IGKV gene is selected from the group consisting of IGKV3-20, IGKV3-11, and IGKV1-39. In some embodiments, the human IGKV gene and the human IGKJ gene are operatively linked. In some embodiments, the human IGKV gene is IGKV3-11. In some embodiments, the human IGKJ gene is selected from the group consisting of IGKJ1 and IGKJ4. In some embodiments, the human IGKV gene is IGKV1-39, and the human IGKJ gene is IGKJ4. In some embodiments, the human IGKV gene is IGKV3-11, and the human IGKJ gene is IGKJ1. In some embodiments, the human IGKV gene is IGKV3-20, and the human IGKJ gene is IGKJ1. In some embodiments, the animal further comprises a promoter sequence operatively linked to the human IGKV gene. In some embodiments, the promoter sequence is within 2500 bp or 3000 bp of the human IGKV gene. In some embodiments, the promoter is the IGKV3-20 promoter, the IGKV3-11 promoter, or the IGKV1-39 promoter.

[0014] In some embodiments, the animal comprises disruption of an endogenous light chain immunoglobulin locus. In some embodiments, the animal is a mouse, and the disruption of the endogenous light chain immunoglobulin locus comprises deletion of one or more mouse IGKV genes in Table 3 and one or more mouse IGKJ genes in Table 4. In some embodiments, the animal is a mouse, and the disruption of the endogenous light chain immunoglobulin locus comprises deletion of the sequence from mouse IGKV2-137 to mouse IGKJ5.

[0015] In some embodiments, the animal comprises endogenous IGKC. In some embodiments, the animal further comprises κ intronic enhancers 5' and / or κ3' enhancers relative to the endogenous IGKC.

[0016] In some implementations, the human light chain variable region is a rearranged sequence.

[0017] In some embodiments, the animal is homozygous relative to the light chain immunoglobulin locus. In some embodiments, the animal is heterozygous relative to the light chain immunoglobulin locus. In some embodiments, the animal includes disruption of the animal's endogenous λ light chain immunoglobulin locus.

[0018] In some implementations, the animal is a rodent (e.g., a mouse).

[0019] In some embodiments, the animal further includes one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHJ genes at the endogenous heavy chain immunoglobulin locus. In some embodiments, the human IGHV gene, human IGHD gene, and human IGHJ gene are operatively linked and are capable of VDJ rearrangement.

[0020] In some embodiments, the animal comprises at least 150 human IGHV genes selected from Table 5, at least 20 human IGHD genes selected from Table 6, and at least 5 human IGHJ genes selected from Table 7. In some embodiments, the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes at an endogenous heavy chain immunoglobulin locus on human chromosome 14 of a human subject. In some embodiments, the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes at an endogenous heavy chain immunoglobulin locus on human chromosome 14 of human cells. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus. In some embodiments, the unmodified human sequence is at least 800 kb.

[0021] In some embodiments, the animal comprises an unmodified human sequence derived from the human heavy chain immunoglobulin locus, from human IGHV(III)-82 to human IGHV1-2. In some embodiments, the animal comprises an unmodified human sequence derived from the human heavy chain immunoglobulin locus, from human IGHV(III)-82 to human IGHV6-1. In some embodiments, the animal comprises an unmodified human sequence derived from the human heavy chain immunoglobulin locus, from human IGHD1-1 to human IGHJ6. In some embodiments, the animal comprises an unmodified human sequence derived from the human heavy chain immunoglobulin locus, from human IGHV(III)-82 to human IGHJ6. In some embodiments, the animal comprises IGHV(III)-82, IGHV7-81, IGHV4-80, IGHV3-79, IGHV(II)-78-1, IGHV5-78, IGHV7-77, IGHV(III)-76-1, IGHV3-76, IGHV3-75, and IGHV(II)-74-1. In some embodiments, the animal comprises IGHV5-10-1 and IGHV3-64D.

[0022] In some embodiments, the animal further comprises, at the endogenous heavy chain immunoglobulin locus: a first sequence comprising one or more human IGHV genes; a second sequence comprising an endogenous sequence; and a third sequence comprising one or more human IGHD genes and one or more human IGHJ genes. In some embodiments, the first, second, and third sequences are operatively linked.

[0023] In some embodiments, the first sequence comprises at least 150 human IGHV genes selected from Table 5. In some embodiments, the first sequence comprises at least 20 human IGHD genes selected from Table 6. In some embodiments, the first sequence is an unmodified sequence derived from a human heavy chain immunoglobulin locus. In some embodiments, the first sequence is at least 800 kb. In some embodiments, the second sequence comprises at least 3 kb of endogenous sequence. In some embodiments, the third sequence comprises at least 20 human IGHD genes selected from Table 6 and at least 5 human IGHJ genes selected from Table 7.

[0024] In some embodiments, the third sequence comprises all human IGHD genes in Table 6 and all human IGHJ genes in Table 7. In some embodiments, the third sequence is an unmodified sequence derived from a human heavy chain immunoglobulin locus. In some embodiments, the third sequence is at least 50 kb. In some embodiments, the animal comprises disruption of the animal's endogenous heavy chain immunoglobulin locus.

[0025] In some embodiments, the animal is a mouse, and the disruption of the animal's endogenous heavy chain immunoglobulin gene loci comprises the deletion of one or more mouse IGHV genes in Table 8, one or more mouse IGHD genes in Table 9, and one or more mouse IGHJ genes in Table 10. In some embodiments, the animal is a mouse, and the disruption of the animal's endogenous heavy chain immunoglobulin gene loci comprises the deletion of sequences from mouse IGHV1-85 to mouse IGHJ4. In some embodiments, the animal comprises one or more endogenous IGHM, IGHδ, IGHG3, IGHG1, IGHG2b, IGHG2a, IGHE, and IGHA genes.

[0026] In some embodiments, the animal is homozygous relative to the heavy chain immunoglobulin locus. In some embodiments, the animal is heterozygous relative to the heavy chain immunoglobulin locus.

[0027] In one aspect, this disclosure provides a genetically modified non-human animal whose genome includes an endogenous light chain immunoglobulin locus, said endogenous light chain immunoglobulin locus comprising: one or more endogenous IGKV genes replaced by one or more human IGKV genes selected from Table 1; and one or more endogenous IGKJ genes replaced by one or more human IGKJ genes selected from Table 2. In some embodiments, the human IGKV gene and the human IGKJ gene are operatively linked to an endogenous IGKC gene.

[0028] In some embodiments, the one or more human IGKV genes are selected from the group consisting of IGKV3-20, IGKV3-11, and IGKV1-39. In some embodiments, the human IGKV gene is IGKV3-11. In some embodiments, the one or more human IGKJ genes are selected from the group consisting of IGKJ1 and IGKJ4. In some embodiments, the animal further includes an insertion of a human IGKJ 3'-UTR sequence. In some embodiments, the human IGKV gene is IGKV1-39, and the human IGKJ gene is IGKJ4. In some embodiments, the human IGKV gene is IGKV3-11, and the human IGKJ gene is IGKJ1. In some embodiments, the human IGKV gene is IGKV3-20, and the human IGKJ gene is IGKJ1. In some embodiments, all endogenous IGKV genes are replaced with the one or more human IGKV genes. In some implementations, all endogenous IGKJ genes are replaced with one or more human IGKJ genes.

[0029] In some embodiments, the animal further includes a promoter sequence preceding the human IGKV gene. In some embodiments, the promoter sequence is within 3000 bp of the human IGKV gene. In some embodiments, the animal further includes a κ intronic enhancer at the 5' endogenous IGKC. In some embodiments, the animal further includes a κ3' enhancer.

[0030] In some embodiments, the animal's genome further includes an endogenous heavy chain immunoglobulin locus comprising one or more endogenous IGHV, endogenous IGHD, and endogenous IGHJ genes replaced by one or more human IGHV, human IGHD, and human IGHJ genes. In some embodiments, the one or more human IGHV, human IGHD, and human IGHJ genes are operatively linked to one or more endogenous IGHM, IGHδ, IGHG, IGHE, and IGHA genes. In some embodiments, the one or more endogenous IGHV, endogenous IGHD, and endogenous IGHJ genes are replaced by at least 150 human IGHV genes in Table 5, at least 20 human IGHD genes in Table 6, and at least 5 human IGHJ genes in Table 7.

[0031] In some embodiments, the animal is a mouse, and at least 180 mouse IGHV genes in Table 8, all mouse IGHD genes in Table 9, and all mouse IGHJ genes in Table 10 are replaced.

[0032] In some embodiments, the animal lacks an endogenous immunoglobulin heavy chain variable region locus capable of rearranging and forming a nucleic acid sequence encoding an endogenous heavy chain variable domain (e.g., mouse heavy chain variable domain). In some embodiments, the animal lacks an endogenous immunoglobulin light chain variable region locus capable of rearranging and forming a nucleic acid sequence encoding an endogenous light chain variable domain (e.g., mouse light chain variable domain).

[0033] In some embodiments, the animal may produce humanized antibodies. In some embodiments, the antibody comprises a light chain variable region encoded by the IGKV and IGKJ genes.

[0034] In one aspect, this disclosure provides cells obtained from animals as described herein. In some embodiments, the cells are B cells expressing chimeric immunoglobulin light chains comprising immunoglobulin light chain variable domains encoded by human IGKV and human IGKJ genes, wherein the human IGKV gene is selected from the group consisting of IGKV3-20, IGKV3-11, and IGKV1-39, and the human IGKJ gene is selected from the group consisting of IGKJ1 and IGKJ4. In some embodiments, the immunoglobulin light chain variable domains are operatively linked to non-human light chain constant regions.

[0035] In some embodiments, B cells express a chimeric immunoglobulin heavy chain comprising a variable domain derived from rearrangements of one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHJ genes. In some embodiments, the variable domain is operatively linked to a non-human heavy chain constant region.

[0036] In some implementations, the cells are embryonic stem (ES) cells.

[0037] In one aspect, this disclosure provides a method for preparing a chimeric antibody that specifically binds to an antigen, the method comprising exposing an animal as described herein to an antigen; generating a hybridoma from cells collected from the animal; and collecting the chimeric antibody generated from the hybridoma.

[0038] In some embodiments, the method further includes sequencing the genome of the hybridoma.

[0039] In one aspect, this disclosure provides a method for preparing an antibody that specifically binds to an antigen, the method comprising: exposing an animal, as described herein, to an antigen; sequencing nucleic acids encoding variable regions of human heavy chain and light chain immunoglobulins in cells, said cells expressing chimeric antibodies that specifically bind to said antigen; and operatively linking in cells the nucleic acids encoding the variable regions of said human heavy chain immunoglobulins to nucleic acids encoding the constant regions of said human heavy chain immunoglobulins, and operatively linking the nucleic acids encoding the variable regions of said human light chain immunoglobulins to nucleic acids encoding the constant regions of said human light chain immunoglobulins.

[0040] In one aspect, this disclosure provides a method for preparing an antibody that specifically binds to an antigen, the method comprising obtaining a nucleic acid sequence encoding variable regions of human heavy chain and light chain immunoglobulins in cells expressing a chimeric antibody that specifically binds to the antigen, wherein the cells are obtained by exposing an animal as described herein to the antigen; operatively linking the nucleic acid encoding the variable region of the human heavy chain immunoglobulin to a nucleic acid encoding a constant region of the human heavy chain immunoglobulin, and operatively linking the nucleic acid encoding the variable region of the human light chain immunoglobulin to a nucleic acid encoding a constant region of the human light chain immunoglobulin; and expressing the nucleic acid in the cells to obtain the antibody.

[0041] In one aspect, this disclosure provides a method for obtaining a nucleic acid encoding an antibody-binding domain that specifically binds to an antigen, the method comprising exposing an animal, as described herein, to an antigen; and sequencing a nucleic acid encoding variable regions of human heavy and light chain immunoglobulins in cells expressing chimeric antibodies that specifically bind to the antigen.

[0042] In one aspect, this disclosure provides a method for obtaining a sample, the method comprising exposing an animal, as described herein, to the antigen; and collecting the sample from the animal. In some embodiments, the sample is spleen tissue, spleen cells, or B cells.

[0043] In one aspect, this disclosure provides a method for preparing a bispecific antibody, the method comprising: expressing in cells a nucleic acid sequence encoding a light chain polypeptide comprising a human VL, a nucleic acid sequence encoding a first heavy chain polypeptide comprising a first human VH, and a nucleic acid sequence encoding a second heavy chain polypeptide comprising a second human VH, wherein the sequence encoding the first VH is obtained from an animal as described herein after exposure to a first antigen, and the sequence encoding the second VH is obtained from the animal or different animals after exposure to a second antigen.

[0044] In some embodiments, the first VH and the VL form a first antigen-binding site that specifically binds to the first antigen. In some embodiments, the second VH and the VL form a second antigen-binding site that specifically binds to the second antigen.

[0045] In one aspect, this disclosure provides an antibody or an antigen-binding fragment thereof comprising a human light chain variable region having a sequence that is at least 90%, 95%, or 98% identical to that of SEQ ID NO:38, 39, or 40.

[0046] In one aspect, this disclosure provides a plurality of antibodies or antigen-binding fragments thereof, wherein each antibody or antigen-binding fragment thereof comprises a human light chain variable region having a sequence that is at least 90%, 95%, or 98% identical to that of SEQ ID NO:38, 39, or 40.

[0047] In one aspect, this disclosure provides a method for preparing an antibody that specifically binds to a target protein, the method comprising: exposing an animal as described herein to the target protein, wherein the animal does not express an endogenous protein homologous to the target protein; and sequencing nucleic acids encoding variable regions of human heavy and light chain immunoglobulins in cells, wherein the cells express an antibody that specifically binds to the target protein.

[0048] In some embodiments, the gene encoding the endogenous protein is disrupted in the animal. In some embodiments, the gene encoding the endogenous protein is knocked out.

[0049] In some embodiments, the endogenous protein is at least 80%, 90%, or 95% homologous to the target protein.

[0050] In some embodiments, the target protein is a human protein. In some embodiments, the target protein is PD-1, CTLA-4, LAG-3, BTLA, PD-L1, CD27, CD28, CD47, CD137, CD154, TIGIT, TIM-3, GITR, SIRPa, or OX40.

[0051] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. This document describes the methods and materials used in this invention; other suitable methods and materials known in the art may also be used. Materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated herein by reference in their entirety. In case of conflict, this specification (including definitions) shall prevail.

[0052] Other features and advantages of the invention will become apparent from the following detailed description, the accompanying drawings, and the claims. Attached Figure Description

[0053] Figure 1A This is a flowchart of a method for introducing human immunoglobulin genes into the mouse genome.

[0054] Figure 1B This is an overview of replacing the variable region of the mouse immunoglobulin heavy chain with the variable region of the human immunoglobulin heavy chain.

[0055] Figure 2A The human κ chain V region gene used at the top is shown.

[0056] Figure 2B The human κ chain J region gene used at the top is shown.

[0057] Figure 3A This is a schematic diagram showing the mouse light chain immunoglobulin gene locus.

[0058] Figure 3B This is an overview of replacing the variable region genes of mouse immunoglobulin light chains with rearranged human IGKV and IGKJ genes.

[0059] Figure 4 This is a schematic diagram illustrating the targeting strategy for humanization of the κ light chain gene.

[0060] Figure 5A is a histogram showing the body weight of wild-type (WT) and hVH / hcVL heterozygous mice.

[0061] Figure 5B is a histogram showing the liver weight of wild-type (WT) and hVH / hcVL heterozygous mice.

[0062] Figure 5C is a histogram showing the thymus weight of wild-type (WT) and hVH / hcVL heterozygous mice.

[0063] Figure 5D is a histogram showing the spleen weight of wild-type (WT) and hVH / hcVL heterozygous mice.

[0064] Figure 5E is a histogram showing the lung weight of wild-type (WT) and hVH / hcVL heterozygous mice.

[0065] Figure 5F is a histogram showing the heart weight of wild-type (WT) and hVH / hcVL heterozygous mice.

[0066] Figure 5G This is a histogram showing the kidney weight of wild-type (WT) and hVH / hcVL heterozygous mice.

[0067] Figure 6A This is a histogram showing the percentage of blood immune cells obtained by flow cytometry. The blood immune cells were derived from wild-type or hVH / hcVL mice.

[0068] Figure 6B This is a histogram showing the percentage of immune cells in the spleen obtained by flow cytometry. The immune cells were derived from wild-type or hVH / hcVL mice.

[0069] Figure 7 This is a histogram showing the percentage of lymph node immune cells obtained by flow cytometry. The lymph node immune cells were derived from wild-type or hVH / hcVL mice.

[0070] Figure 8A It shows proto-B cells (B220) in bone marrow B cells. 低 CD43 高 IgM 低 ), pre-B cells (B220) 低 CD43 中 IgM 低 ) and immature B cells (B220) 高 CD43 低 IgM 高 The percentage of the group. Bone marrow B cells are derived from wild-type or hVH / hcVL mice.

[0071] Figure 8B The image shows plasma cells (B220) in bone marrow B cells. 低 IgM - IgD - CD138 + ) and memory B cells (B220) + IgM + IgD - CD38+ The percentage of the group. Bone marrow B cells are derived from wild-type or hVH / hcVL mice.

[0072] Figure 9 This shows transition type 1 (T1, B220) in spleen B cells. + IgM + IgD - Transitional Type 2 (T2, B220) + IgM + IgD + ) and mature B cells (M, B220) + IgM 低 IgD + The percentage of splenic B cells. Splenic B cells are derived from wild-type or hVH / hcVL mice.

[0073] Figure 10A shows plasma cells (B220) in spleen B cells. 低 IgM - IgD - CD138 + The percentage of splenic B cells. Splenic B cells are derived from wild-type or hVH / hcVL mice.

[0074] Figure 10B shows memory B cells (B220) in spleen B cells. + IgM + IgD - CD38 + The percentage of splenic B cells. Splenic B cells are derived from wild-type or hVH / hcVL mice.

[0075] Figure 10C This shows marginal zone B cells (MZ, B220) in spleen B cells. + CD21 + CD23 - ) and follicular B cells (F0, B220) + CD21 低 CD23 + The percentage of splenic B cells. Splenic B cells are derived from wild-type or hVH / hcVL mice.

[0076] Figure 11A shows the flow cytometry results of mB220-labeled spleen B cells from wild-type female mice.

[0077] Figure 11B shows the flow cytometry results of mB220-labeled spleen B cells from hVH / hcVL female mice.

[0078] Figure 11C shows the flow cytometry results of mB220-labeled spleen B cells from wild-type male mice.

[0079] Figure 11D shows the flow cytometry results of mB220-labeled spleen B cells from hVH / hcVL male mice.

[0080] Figure 11E shows the flow cytometry results of spleen B cells labeled with mIgGκ-FITC and mIgGλ-PE from wild-type female mice.

[0081] Figure 11F shows the flow cytometry results of spleen B cells labeled with mIgGκ-FITC and mIgGλ-PE from hVH / hcVL female mice.

[0082] Figure 11G shows the flow cytometry results of spleen B cells labeled with mIgGκ-FITC and mIgGλ-PE from wild-type male mice.

[0083] Figure 11H shows the flow cytometry results of spleen B cells labeled with mIgGκ-FITC and mIgGλ-PE from hVH / hcVL male mice.

[0084] Figure 11I This is a histogram showing the percentages of mIgGλ-PE labeled B cells (mIgGλ) and mIgGκ-FITC labeled spleen B cells (mIgGκ).

[0085] Figure 12A This shows transition type 1 (T1, B220) in B cells of lymph nodes. + IgM + IgD - Transitional Type 2 (T2, B220) + IgM + IgD + ) and mature B cells (M, B220) + IgM 低 IgD + The percentage of the B cells in the lymph nodes. The B cells in the lymph nodes were derived from wild-type or hVH / hcVL mice.

[0086] Figure 12B The image shows plasma cells (B220) in B cells of lymph nodes. 低 IgM - IgD - CD138 + ) and memory B cells (B220) + IgM + IgD - CD38 + The percentage of the B cells in the lymph nodes. The B cells in the lymph nodes were derived from wild-type or hVH / hcVL mice.

[0087] Figure 13A shows the flow cytometry results of mB220-labeled lymph node B cells from wild-type female mice.

[0088] Figure 13B shows the flow cytometry results of mB220-labeled lymph node B cells from hVH / hcVL female mice.

[0089] Figure 13C shows the flow cytometry results of mB220-labeled lymph node B cells from wild-type male mice.

[0090] Figure 13D shows the flow cytometry results of mB220-labeled lymph node B cells from hVH / hcVL male mice.

[0091] Figure 13E shows the flow cytometry results of lymph node B cells labeled with mIgGκ-FITC and mIgGλ-PE from wild-type female mice.

[0092] Figure 13F shows the flow cytometry results of mIgGκ-FITC and mIgGλ-PE labeled lymph node B cells from hVH / hcVL female mice.

[0093] Figure 13G shows the flow cytometry results of lymph node B cells labeled with mIgGκ-FITC and mIgGλ-PE from wild-type male mice.

[0094] Figure 13H The results of flow cytometry analysis of mIgGκ-FITC and mIgGλ-PE labeled lymph node B cells from hVH / hcVL male mice are shown.

[0095] Figure 13I This is a histogram showing the percentages of mIgGλ-PE labeled B cells (mIgGλ) and mIgGκ-FITC labeled lymph node B cells (mIgGκ).

[0096] Figure 13J The concentrations of serum immunoglobulin (Ig) isoforms in wild-type (WT) or pre-antigen-immunized hVH / hcVL mice are shown. Ig isoform concentrations were determined by ELISA.

[0097] Figure 14 This is a schematic diagram highlighting the light chain immunoglobulin gene locus on human chromosome 2 (not drawn to scale). V HK J represents a segment of the IGKV gene cluster. HK The segment representing the IGKJ gene cluster, and C HK Represents the IGKC gene.

[0098] Figure 15Lists of human distal Vκ cluster IGKV genes and human proximal Vκ cluster IGKV genes are shown.

[0099] Figure 16 This is a schematic diagram showing the human immunoglobulin heavy chain (IGH) locus on chromosome 14 (14q32.33).

[0100] Figure 17 This is a schematic diagram of the mouse (Mus musculus) IGH locus on chromosome 12 (12F2) (strain C57BL / 6).

[0101] Figure 18 This is a schematic diagram showing the human immunoglobulin κ chain (IGK) gene locus on chromosome 2 (2p11.2).

[0102] Figure 19 This is a schematic diagram showing the mouse (Mus musculus) IGK gene locus on chromosome 6 (6C1).

[0103] Figure 20 The IMGT lineage of the human heavy chain immunoglobulin locus (IGH) is listed.

[0104] Figure 21 The IMGT lineage of mouse IGH is listed.

[0105] Figure 22 The IMGT lineage of the human κ chain immunoglobulin locus (IGK) is listed.

[0106] Figure 23 The IMGT lineage of mouse IGK is listed.

[0107] Figure 24 It shows the results in wild type and hVH H / H / hcVL K / + Antigen-specific antibody titers in mice after three immunizations with the first test antigen.

[0108] Figure 25 It shows the results in wild type and hVH H / H / hcVL K / + Antigen-specific antibody titers in mice after three immunizations with the second test antigen.

[0109] Figure 26A It shows that in hVH H / H / hcVL K / + IGHV utilization rate in mice (frequency >1%).

[0110] Figure 26B It shows that in hVH H / H / hcVLK / + IGHV utilization rate in mice (frequency <1%).

[0111] Figure 26C It shows that in hVH H / H / hcVL K / + IGHD utilization in mice.

[0112] Figure 26D It shows that in hVH H / H / hcVL K / + IGHJ utilization rate in mice.

[0113] Figure 26E It shows that in hVH H / H / hcVL K / K IGHV utilization rate in mice (frequency >1%).

[0114] Figure 26F It shows that in hVH H / H / hcVL K / K IGHV utilization rate in mice (frequency <1%).

[0115] Figure 26G It shows that in hVH H / H / hcVL K / K IGHJ utilization rate in mice.

[0116] Figure 27A It shows the source from hVH H / H / hcVL K / + Histogram of the amino acid length distribution of the heavy chain CDR3 in mice.

[0117] Figure 27B It shows the source from hVH H / H / hcVL K / K Histogram of the amino acid length distribution of the heavy chain CDR3 in mice.

[0118] Figure 28A It shows that in hVH H / H / hcVL K / + Amino acid frequencies on the heavy chain CDR3 (CDR3 length equal to 17 amino acids) in mice.

[0119] Figure 28B It shows that in hVH H / H / hcVL K / + Amino acid frequencies on the heavy chain CDR3 (CDR3 length equal to 19 amino acids) in mice.

[0120] Figure 28C It shows that in hVH H / H / hcVL K / +Amino acid frequencies on the heavy chain CDR3 (CDR3 length equal to 21 amino acids) in mice.

[0121] Figure 28D It shows that in hVH H / H / hcVL K / K Amino acid frequencies on the heavy chain CDR3 (CDR3 length equal to 17 amino acids) in mice.

[0122] Figure 29 It shows that in hVH H / H / hcVL K / + The frequency of heavy chain CDR3s with different lengths containing multiple cysteine ​​residues, one cysteine ​​residue, and two cysteine ​​residues in mice.

[0123] Figure 30A It shows that in hVH H / H / hcVL K / + Somatic cell hypervariation ratio of amino acids (AA) encoded in rearranged human IGKV3-11 / J1 sequences in mice.

[0124] Figure 30B It shows that in hVH H / H / hcVL K / + Somatic hypervariation ratio of rearranged human IGKV3-11 / J1 DNA in mice.

[0125] Figure 30C It shows that in hVH H / H / hcVL K / K Somatic hypervariation ratio of rearranged human IGKV3-11 / J1 DNA in mice.

[0126] Figure 31 The epitope clustering results of 15 human anti-antigen A antibodies are shown.

[0127] Figure 32 The sequences described in this disclosure are listed.

[0128] Figure 33A VDJ recombination analysis of antibody target antigen D in hVH is shown. H / H / hcVL K / K Heavy chain diversity in mice.

[0129] Figure 33B VDJ recombination analysis of antibody target antigen E in hVH is shown. H / H / hcVL K / K Heavy chain diversity in mice.

[0130] Figures 34A-34B show the distribution of association rate (kon) and dissociation rate (koff) of antibody target antigen D.

[0131] Figures 34C-34D show the distribution of association rate (kon) and dissociation rate (koff) of antibody target antigen E.

[0132] Figure 35A The binding affinity (KD) distribution of antibody target antigen D is shown.

[0133] Figure 35B The binding affinity (KD) distribution of antibody target antigen E is shown. Detailed Implementation

[0134] Monoclonal antibodies typically consist of two heavy chains, with each heavy chain monomer associated with the same light chain. Due to their target specificity, monoclonal antibodies can usually bind to a single target. However, in drug development, there is a need for antibodies capable of binding to two different antigens or epitopes. For example, CD3-specific antibodies are often paired with antibodies specific to multiple tumor-associated antigens to produce bispecific antibodies for cancer treatment. The ability of bispecific antibodies to bind to two different antigens or epitopes offers broad clinical applications. To date, at least two bispecific antibodies are on the market, and numerous other bispecific antibodies are undergoing clinical trials.

[0135] Bispecific antibodies typically consist of two distinct heavy chains and two distinct light chains. Generating them in a single host cell is challenging because the random pairing of the two heavy and two light chains results in the expression of 10 different IgG species, only one of which is the target format. Modifications to the heavy chain using a club-and-mortar structure have been proposed. Several other modifications to the light chain have also been proposed. However, these additional modifications can adversely affect biochemical and / or biophysical properties, serum half-life, and / or stability, leading to poor efficacy, instability, and high immunogenicity. A method for preparing bispecific antibodies that does not overly rely on antibody engineering is needed.

[0136] This disclosure relates to genetically modified animals and cells having humanized light chain immunoglobulin loci (e.g., κ chain loci) and / or humanized heavy chain immunoglobulin loci. In one aspect, the humanized light chain immunoglobulin loci have a limited set of IGKV and IGKJ genes. The genetically engineered animals, through a lengthy and complex antibody selection process within the organism, make biologically appropriate choices when pairing a diverse set of human heavy chain variable domains with a limited number of human light chain variable domain options. The animals are engineered to exhibit a limited number of human light chain variable domain options combined with a broad range of human heavy chain variable domain options. Faced with the challenge of immunogens, the animals develop antibodies against the immunogens, primarily or entirely limited by the number of light chain options in their lineage.

[0137] In various embodiments, antibodies produced in genetically modified animals have a heavy chain that can bind to the same or substantially the same light chain. This is particularly useful in the preparation of bispecific antibodies. For example, such animals can be immunized with a first antigen to produce B cells that express antibodies that specifically bind to the first antigen. The animal (or an animal with the same modification) can be immunized with a second antigen to produce B cells that express antibodies that specifically bind to the second antigen. VHs can be cloned from the first and second B cells. Two VHs can be paired with the same light chain VL to prepare bispecific antibodies. Therefore, it is not necessary to associate a light chain with a specific heavy chain through antibody engineering (e.g., introducing modifications to the sequence). This can greatly improve the success rate of bispecific antibody development. In fact, antibodies or sequences as described herein can be further combined with each other to prepare multispecific antibodies.

[0138] To obtain a limited lineage of light chain variable domain options, the animal is engineered to restrict its ability to generate animal light chain variable domains with natural diversity. The endogenous animal locus can then be modified by a selected exogenous, suitable human light chain variable region gene sequence, operatively linked to the endogenous animal light chain constant domain, such that the rearranged exogenous human variable region gene sequence can encode a rearranged chimeric light chain (human variable endogenous constant), or that an unrearranged exogenous human variable region gene sequence with limited diversity can be rearranged and recombinated to encode a rearranged chimeric light chain.

[0139] The genetically modified animals described herein can possess several other advantages. For example, in some cases, the genetically modified animals described herein possess both the complete human heavy chain variable region genes and rearranged human light chain variable region genes (e.g., human IGKV1-39 / IGKJ4). Furthermore, because the entire heavy chain variable region (unmodified or with limited modification) of the human immunoglobulin locus is introduced into the animal genome, these genes can undergo VDJ recombination in a manner very similar to that occurring in humans. Additionally, due to efficient VDJ recombination, antibody production can be highly efficient and at a rate similar to that of normal production.

[0140] As used herein, the term "antibody" refers to an immunoglobulin molecule comprising four polypeptide chains interconnected by disulfide bonds: two heavy (H) chains and two light (L) chains. Each heavy chain contains a heavy chain variable (VH) domain and a heavy chain constant region (CH). Each light chain contains a light chain variable (VL) domain and a light chain constant region (CL). The VH and VL domains can be further subdivided into hypervariable regions (called complementarity-determining regions (CDRs)) scattered with more conserved regions called framework regions (FRs). Each VH and VL contains three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (heavy chain CDRs can be abbreviated as HCDR1, HCDR2, and HCDR3; light chain CDRs can be abbreviated as LCDR1, LCDR2, and LCDR3). The term "high-affinity" antibody refers to an antibody relative to its target epitope K D Approximately 10 -8 M or lower (e.g., approximately or less than 1×10⁻⁶) -8 M, 1×10 -9 M, 1×10 -10 M or 1×10 -11 Antibodies for M). In some implementations, K D It can be achieved through surface plasmon resonance, for example, BIACORE. TM Or use ELISA to measure.

[0141] As used herein, the term "antigen-binding fragment" refers to a portion of a full-length antibody that is capable of specifically binding to an antigen. In some embodiments, the antigen-binding fragment contains at least one variable domain (e.g., a variable domain of the heavy chain or a variable domain of the light chain). Non-limiting examples of antibody fragments include, for example, Fab, Fab', F(ab')2, and Fv fragments.

[0142] As used herein, the term "human antibody" refers to an antibody encoded by nucleic acids present in the human body (e.g., rearranged human immunoglobulin heavy or light chain loci). In some embodiments, human antibodies are collected from humans or generated in human cell cultures (e.g., human hybridoma cells). In some embodiments, human antibodies are generated in non-human cells (e.g., mouse or hamster cell lines). In some embodiments, human antibodies are generated in bacterial or yeast cells. In some embodiments, human antibodies are generated in transgenic non-human animals (e.g., mice) containing unrearranged or rearranged human immunoglobulin loci (e.g., heavy or light chain human immunoglobulin loci).

[0143] As used herein, the term "chimeric antibody" refers to an antibody containing a sequence present in at least two different antibodies (e.g., antibodies from two different mammalian species, such as human and mouse antibodies). A non-limiting embodiment of a chimeric antibody is an antibody containing a variable domain sequence of a human antibody (e.g., all or part of a light chain and / or heavy chain variable domain sequence) and a constant domain of a non-human antibody. Further embodiments of chimeric antibodies are described herein and are known in the art.

[0144] As used herein, the term "humanized antibody" refers to a non-human antibody containing sequences derived from non-human (e.g., mouse) immunoglobulins and sequences derived from human immunoglobulins.

[0145] As used herein, the terms “subject” and “patient” are used interchangeably throughout the specification and are used to describe animals, humans, or non-humans. This disclosure covers both veterinary and non-veterinary applications. A human patient can be an adult or a minor (e.g., a person under the age of 18). In addition to humans, patients include, but are not limited to, mice, rats, hamsters, guinea pigs, rabbits, ferrets, cats, dogs, and primates. This includes, for example, non-human primates (e.g., monkeys, chimpanzees, gorillas, etc.), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, pigs (e.g., piglets, miniature pigs), horses, dogs, felines, bovines, and other domesticated, farm, and zoo animals.

[0146] As used herein, when referring to antibodies, the phrases “specifically binds to” and “specifically binds to…” mean that the antibody interacts with its target molecule, preferably with other molecules, because the interaction depends on the presence of a specific structure on the target molecule (i.e., an antigenic determinant or epitope); in other words, the reagent typically recognizes and binds to molecules that include a specific structure, rather than all molecules. Antibodies that specifically bind to a target molecule can be called target-specific antibodies.

[0147] As used herein, the terms “polypeptide,” “peptide,” and “protein” are used interchangeably and refer to an amino acid polymer of any length having at least two amino acids.

[0148] As used herein, the terms “polynucleotide,” “nucleic acid molecule,” and “nucleic acid sequence” are used interchangeably and refer to a nucleotide polymer of any length having at least two nucleotides, including but not limited to DNA, RNA, DNA / RNA hybrids, and their modifications.

[0149] As used herein, the term "unmodified human sequence" refers to a sequence derived from a human subject, human cell, cultured human cell, or human cell line, wherein the sequence is identical to the genetic sequence of the human subject, human cell, cultured human cell, or human cell line.

[0150] As used herein, the term "bispecific antibody" refers to an antibody capable of selectively binding to two or more epitopes. Bispecific antibodies typically comprise two distinct heavy chains, each specifically binding to a different epitope—either on two different molecules (e.g., different epitopes on two different immunogens) or on the same molecule (e.g., different epitopes on the same immunogen). The epitopes specifically bound by a bispecific antibody can be on the same or different targets (e.g., on the same or different proteins). For example, bispecific antibodies can be prepared by binding heavy chains that recognize different epitopes of the same immunogen. For example, nucleic acid sequences encoding variable sequences of the heavy chains can be fused to nucleic acid sequences encoding constant regions of the same or different heavy chains, wherein the variable sequences of the heavy chains recognize different epitopes of the same immunogen, and such sequences can be expressed in cells expressing immunoglobulin light chains. A typical bispecific antibody has two heavy chains, each with three heavy chain CDRs, followed by a (N-terminal to C-terminal) CH1 domain, a hinge, a CH2 domain, and a CH3 domain, and an immunoglobulin light chain. The immunoglobulin light chain does not confer epitope binding specificity but can be associated with each heavy chain, or can be associated with each heavy chain and can bind one or more epitopes bound by the heavy chain epitope binding region, or can be associated with each heavy chain and cause one or two heavy chains to bind to one or two epitopes.

[0151] As used herein, the term "shared light chain antibody" refers to an antibody having two or more identical light chains. In some embodiments, a shared light chain antibody is a shared light chain bispecific antibody.

[0152] Restriction κ light chain immunoglobulin locus

[0153] The κ chain immunoglobulin locus (also known as IGK or immunoglobulin κ locus) is a region on a chromosome (e.g., human chromosome 2) containing the light chain gene for human antibodies (or immunoglobulins). Similarly, the immunoglobulin light chain gene can undergo a series of rearrangements, resulting in the production of mature immunoglobulin light chain nucleic acids (e.g., the κ chain).

[0154] The joining of the V region (also known as the IGKV gene) and the J region (also known as the IGKJ gene) produces consecutive exons that encode the entire light chain variable domain. In unrearranged DNA, the V gene region (or IGKV gene cluster) is located relatively far from the C region. The J gene region (or IGKJ gene cluster) is located near the C region. The joining of the V and J gene regions also brings the V gene closer to the C region sequence. The rearranged V region J gene region is separated from the C region sequence by only one intron. To produce complete immunoglobulin light chain messenger RNA, the V region exons are ligated to the C region sequence post-transcriptionally via RNA splicing.

[0155] The human light chain immunoglobulin locus is located on human chromosome 2. Table 1 lists the IGKV genes and their relative order at this locus. The human IGKV gene set consists of several distinct groups, including the IGKV1 gene (containing all IGKV genes starting with IGKV1, also known as VκI), the IGKV2 gene (containing all IGKV genes starting with IGKV2, also known as VκII), the IGKV3 gene (containing all IGKV genes starting with IGKV3, also known as VκIII), the IGKV4 gene (containing all IGKV genes starting with IGKV4, also known as VκIV), the IGKV5 gene (containing all IGKV genes starting with IGKV5, also known as VκV), the IGKV6 gene (containing all IGKV genes starting with IGKV6, also known as VκVI), and the IGKV7 gene (containing all IGKV genes starting with IGKV7, also known as VκVII).

[0156] These IGKV genes on human chromosome 2 also form two clusters: the proximal Vκ cluster and the distal Vκ cluster. Figure 14 The sequences in the two clusters are similar, but not identical. This large-segment replication of the sequences occurred when the human lineage began to diverge from its most recent common ancestor with other large apes. Figure 15 The relevant IGKV genes in each cluster are summarized.

[0157] Table 1. List of IGKV genes on human chromosome 2

[0158]

[0159]

[0160] Table 2 lists all IGKJ genes on human chromosome 2 and their relative sequences. The immunoglobulin κ constant region (IGKC) gene, encoding the light chain immunoglobulin constant domain, is located after the IGKV and IGKJ genes. These genes and their sequences are also shown in Table 2. Figure 18 and Figure 22 middle.

[0161] Table 2. List of IGKJ genes on human chromosome 2

[0162] Gene name order Gene name order IGKJ1 77 IGKJ4 80 IGKJ2 78 IGKJ5 81 IGKJ3 79

[0163] The mouse light chain immunoglobulin gene locus is located on mouse chromosome 6. Table 3 lists the IGKV gene and its relative order at this locus.

[0164] Table 3. List of IGKV genes on mouse chromosome 6

[0165]

[0166]

[0167]

[0168] Gm9728 and Amd-ps2 are also located at this locus. The relative sequence of Gm9728 is 4, and the relative sequence of Amd-ps2 is 134. Table 4 lists all IGKJ genes on mouse chromosome 6 and their relative sequences. The IGKC gene, encoding the light chain immunoglobulin constant domain, follows the IGKV and IGKJ genes. These genes and their sequences are also shown in Table 4. Figure 19 and Figure 23 middle.

[0169] Table 4. List of IGKJ genes on mouse chromosome 6

[0170] Gene name order Gene name order IGKJ1 166 IGKJ4 169 IGKJ2 167 IGKJ5 170 IGKJ3 168

[0171] This disclosure provides genetically modified non-human animals comprising one, two, three, or no more than three human IGKV genes and one, two, three, or no more than three human IGKJ genes. In some embodiments, the human IGKV and human IGKJ genes are located at an endogenous light chain immunoglobulin locus. In some embodiments, the human IGKV and human IGKJ genes are rearranged sequences. In some embodiments, they are non-rearranged sequences.

[0172] In some embodiments, the human IGKV gene is selected from any one of the IGKV genes in Table 1. In some embodiments, the human IGKJ gene is selected from any one of the IGKJ genes in Table 2.

[0173] In some embodiments, the animal contains only one human IGKV gene and one human IGKJ gene. In some embodiments, the IGKV gene is selected from any one of the IGKV genes in Table 1. In some embodiments, the IGKJ gene is selected from any one of the IGKJ genes in Table 2.

[0174] In some embodiments, the animal contains a human IGKV gene selected from IGKV3-20, IGKV1-39, IGKV1D-39, IGKV3-11, IGKV3-15, and IGKV4-1. In some embodiments, the animal contains a human IGKJ gene selected from IGKJ1, IGKJ2, and IGKJ4.

[0175] In some embodiments, the animal contains a human IGKV gene selected from IGKV3-20, IGKV3-11, IGKV3-15, IGKV1-39, IGKV1D-39, IGKV1-12, and IGKV1D-12. In some embodiments, the animal contains a human IGKJ gene selected from IGKJ1, IGKJ4, and IGKJ2.

[0176] In some embodiments, the animal contains the human IGKV gene selected from IGKV3-20, IGKV3-11, and IGKV1-39. In some embodiments, the animal contains the human IGKJ gene selected from IGKJ1 and IGKJ4.

[0177] In some embodiments, the animal contains a promoter sequence preceding the first nucleotide of the human IGKV gene. In some embodiments, the promoter sequence is located within or approximately 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3500, 4000, 4500, or 5000 bp prior to the human IGKV gene. In some embodiments, the promoter is the human IGKV3-20 promoter, the human IGKV1-39 promoter, or the human IGKV3-11 promoter. In some embodiments, the promoter sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to nucleotides 1-2000 of SEQ ID NO:35, SEQ ID NO:36, or SEQ ID NO:37.

[0178] In some embodiments, the animal comprises an auxiliary sequence following the last nucleotide of the human IGKJ gene. In some embodiments, the auxiliary sequence comprises a mouse IGKJ 3'-UTR sequence or a human IGKJ 3'UTR sequence. In some embodiments, the sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:6 or SEQ ID NO:7.

[0179] In various embodiments, one or more suitable enhancers may be retained in the animal. For example, when the κ locus is modified to replace the endogenous κ variable region gene segment with a human κ variable region gene segment, the κ intronic enhancer and the κ3' enhancer are functionally maintained or undisturbed. In some embodiments, the modified κ locus may be hypermutated in recipient cells. In some embodiments, the degree of somatic hypermutation is substantially the same as or similar to that of the wild-type κ locus. In some embodiments, at least 50%, 60%, 70%, 80%, 90%, or 95% of the human light chain variable region in the antibody (before or after antigen immunization) has at least one somatic mutation. In some embodiments, at least 50%, 60%, 70%, 80%, 90%, or 95% of the human light chain variable region in the antibody (before or after antigen immunization) has at least two somatic mutations. In some implementations, at least 50%, 60%, 70%, 80%, 90%, or 95% of the human light chain variable region (before or after antigen immunization) of the antibody has at least three somatic mutations.

[0180] In some embodiments, the animal contains endogenous IGKC. In some embodiments, the IGKV gene and / or IGKJ gene are operatively linked to the IGKC gene (e.g., the endogenous IGKC gene).

[0181] In some implementations, the IGKV and IGKJ genes are operatively linked together.

[0182] In some embodiments, the animal contains endogenous IGKC. In some embodiments, the IGKV and / or IGKJ genes are operatively linked together. VJ recombination can occur between these genes and produce functional antibodies. In some embodiments, the IGKV and IGKJ genes are rearranged at the endogenous κ-chain immunoglobulin locus.

[0183] In some embodiments, the animal comprises disruption of an endogenous light chain immunoglobulin locus. In some embodiments, disruption of the endogenous light chain immunoglobulin locus includes the deletion of one or more endogenous IGKV genes and one or more endogenous IGKJ genes.

[0184] In some embodiments, the animal is a mouse. Disruptions in the endogenous light chain immunoglobulin loci of the animal include the deletion of at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, or 163 mouse IGKV genes (e.g., genes shown in Table 3). In some embodiments, the disruption comprises the deletion of about or at least one, two, three, four, five, six, seven, eight, nine, or ten mouse IGKV genes selected from IGKV2-137, IGKV1-136, IGKV1-135, IGKV14-134-1, IGKV17-134, IGKV1-133, IGKV1-132, IGKV1-131, IGKV14-130, and IGKV9-129. In some embodiments, the mice still contain about or at least one, two, three, four, five, six, seven, eight, nine, or ten mouse IGKV genes selected from IGKV2-137, IGKV1-136, IGKV1-135, IGKV14-134-1, IGKV17-134, IGKV1-133, IGKV1-132, IGKV1-131, IGKV14-130, and IGKV9-129.

[0185] In some embodiments, the disruption comprises the deletion of about or at least one, two, three, four, five, six, seven, eight, nine, or ten mouse IGKV genes selected from IGKV3-10, IGKV3-9, IGKV3-8, IGKV3-7, IGKV3-6, IGKV3-5, IGKV3-4, IGKV3-3, IGKV3-2, and IGKV3-1. In some embodiments, the mouse still contains about or at least one, two, three, four, five, six, seven, eight, nine, or ten mouse IGKV genes selected from IGKV3-10, IGKV3-9, IGKV3-8, IGKV3-7, IGKV3-6, IGKV3-5, IGKV3-4, IGKV3-3, IGKV3-2, and IGKV3-1.

[0186] In some embodiments, the disruption comprises the deletion of about or at least one, two, three, four, or five mouse IGKJ genes selected from IGKJ1, IGKJ2, IGKJ3, IGKJ4, and IGKJ5. In some embodiments, the mouse still contains about or at least one, two, three, four, or five mouse IGKJ genes selected from IGKJ1, IGKJ2, IGKJ3, IGKJ4, and IGKJ5 (e.g., IGKJ5).

[0187] In some embodiments, the disruption in the animal's endogenous κ light chain immunoglobulin locus comprises the deletion of an endogenous sequence of about or at least 500 kb, 600 kb, 700 kb, 800 kb, 900 kb, 1000 kb, 1500 kb, 2000 kb, 2500 kb, 3000 kb, or 3500 kb.

[0188] In some implementations, the missing sequence begins from IGKV2-137 to IGKJ4, from IGKV1-136 to IGKJ4, from IGKV1-135 to IGKJ4, from IGKV2-137 to IGKJ5, from IGKV1-136 to IGKJ5, or from IGKV1-135 to IGKJ5 (e.g., from IGKV2-137 to IGKJ5).

[0189] In some embodiments, the animal comprises about or at least one, two, three, four, five, six, seven, eight, nine, or ten sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to sequences in the human light chain immunoglobulin locus. In some embodiments, the length of the sequence is about or at least 2 kb or 3 kb. In some embodiments, the length of the sequence does not exceed 4 kb.

[0190] In some embodiments, the animal contains one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) rearranged human IGKV / IGKJ sequences. In some embodiments, the rearranged human IGKV / IGKJ sequences are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:35 (e.g., nucleotides 2001-2512 of SEQ ID NO:35). In some implementations, the rearranged human IGKV / IGKJ sequence is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:36 (e.g., nucleotides 2001-2551 of SEQ ID NO:36). In some implementations, the rearranged human IGKV / IGKJ sequence is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:37 (e.g., nucleotides 2001-2572 of SEQ ID NO:37).

[0191] In some implementations, the length of the rearranged human IGKV / IGKJ sequence is approximately or at least 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4500, or 5000 bp. In some implementations, the rearranged human IGKV / IGKJ sequence is less than 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, or 3100 bp.

[0192] In some embodiments, the animal may produce an immunoglobulin (e.g., IgG) comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the same light chain variable region as SEQ ID NO:38. In some embodiments, the animal may produce an immunoglobulin (e.g., IgG) comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the same light chain variable region as SEQ ID NO:39. In some embodiments, the animal may produce an immunoglobulin (e.g., IgG) comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the same light chain variable region as SEQ ID NO:40. In some embodiments, the light chain variable region may have 1, 2, 3, 4, or 5 mutations compared to SEQ ID NO:38, 39, or 40. In some embodiments, the light chain constant domain has a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:41.

[0193] In some embodiments, the animal may have one, two, three, four, five, six, seven, eight, nine, or ten unmodified human sequences. In some embodiments, the length of the unmodified human sequence is approximately or at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 kb.

[0194] In some embodiments, the light chain variable region has the sequence SEQ ID NO:38, which has 0, 1, or 2 mutations. In some embodiments, the light chain variable region has the sequence SEQ ID NO:39, which has 0, 1, or 2 mutations. In some embodiments, the light chain variable region has the sequence SEQ ID NO:40, which has 0, 1, or 2 mutations.

[0195] Furthermore, in some cases, the entire mouse IGKV and IGKJ genes (both non-pseudogenes) are knocked out, and the light chain variable region will not have any sequences encoded by mouse-derived sequences, thereby minimizing immunogenicity in humans. In various embodiments, the light chain variable region is capable of somatic mutation.

[0196] Genetically modified heavy chain immunoglobulin locus

[0197] Heavy chain immunoglobulin loci (also known as IGH or immunoglobulin heavy chain loci) are regions on chromosomes (e.g., human chromosome 14) that contain human antibody (or immunoglobulin) heavy chain genes.

[0198] This region represents the phylogenetic organization of heavy chain loci. Loci include V (variable), D (diversity), J (connectivity), and C (constant) segments. Genes in the V region form the V gene cluster (also known as the IGHV gene cluster). Genes in the D region form the D gene cluster (also known as the IGHD gene cluster). Genes in the J region form the J gene cluster (also known as the IGHJ gene cluster).

[0199] During B cell development, a DNA-level recombination event links a single D region (also known as the IGHD gene) to a J region (also known as the IGHJ gene); the fused DJ exon of this partially rearranged DJ region is then linked to the V region (also known as the IGHV gene). The rearranged VDJ region containing the fused VDJ exon is then transcribed and fused at the RNA level to the IGHM constant region; this transcript encodes the μ heavy chain. Later in development, B cells produce VDJ-Cμ-Cδ premessenger RNA, which is selectively spliced ​​to encode either the μ or δ heavy chain. Mature B cells in lymph nodes undergo transitional recombination, resulting in a fused VDJ gene region adjacent to one of the IGHG, IGHA, or IGHE gene regions, with each cell expressing the γ, α, or ε heavy chain. The potential recombination of many different IGHV genes with several IGHJ genes provides broad antigen recognition. Additional diversity is achieved through conjugation diversity, which arises from the random addition of nucleotides by terminal deoxynucleotidyl transferases and somatic hypermutation, occurring during B cell maturation in the spleen and lymph nodes. Several V, D, J, and C regions are known not to encode proteins and are considered pseudogene regions (often simply referred to as pseudogenes).

[0200] The human heavy chain immunoglobulin locus is located on human chromosome 14. Table 5 lists the IGHV gene and its relative order at this locus.

[0201] Table 5. List of IGHV genes on human chromosome 14

[0202]

[0203]

[0204] RPS8P1, ADAM6, and KIAA0125 are also located at this locus. The relative sequence of RPS8P1 is 160, that of ADAM6 is 161, and that of KIAA0125 is 164. Table 6 lists all IGHD genes and their relative sequences on human chromosome 14. Table 7 lists all IGHJ genes and their relative sequences on human chromosome 14. Genes containing the immunoglobulin constant domain are located after the IGHV, IGHD, and IGHJ genes. These genes include (in the following order): immunoglobulin heavy chain constant μ (IGHM), immunoglobulin heavy chain constant δ (IGHδ), immunoglobulin heavy chain constant γ3 (IGHG3), immunoglobulin heavy chain constant γ1 (IGHG1), immunoglobulin heavy chain constant εP1 (pseudogene) (IGHEP1), immunoglobulin heavy chain constant α1 (IGHA1), immunoglobulin heavy chain constant γP (nonfunctional) (IGHGP), immunoglobulin heavy chain constant γ2 (IGHG2), immunoglobulin heavy chain constant γ4 (IGHG4), immunoglobulin heavy chain constant ε (IGHE), and immunoglobulin heavy chain constant α2 (IGHA2). These genes and their order are also shown in... Figure 16 and Figure 20 middle.

[0205] Table 6. List of IGHD genes on human chromosome 14

[0206] Gene name order Gene name order Gene name order Gene name order IGHD1-1 165 IGHD2-8 172 IGHD2-15 179 IGHD3-22 186 IGHD2-2 166 IGHD3-9 173 IGHD3-16 180 IGHD4-23 187 IGHD3-3 167 IGHD3-10 174 IGHD4-17 181 IGHD5-24 188 IGHD4-4 168 IGHD4-11 175 IGHD5-18 182 IGHD6-25 189 IGHD5-5 169 IGHD5-12 176 IGHD6-19 183 IGHD1-26 190 IGHD6-6 170 IGHD6-13 177 IGHD1-20 184 * IGHD1-7 171 IGHD1-14 178 IGHD2-21 185 IGHD7-27 192

[0207] Table 7. List of IGHJ genes on human chromosome 14

[0208] Gene name order Gene name order IGHJ1P 191 IGHJ4 197 IGHJ1 193 IGHJ5 198 IGHJ2 194 IGHJ3P 199 IGHJ2P 195 IGHJ6 200 IGHJ3 196

[0209] The mouse heavy chain immunoglobulin gene locus is located on mouse chromosome 12. Table 8 lists the IGHV gene and its relative order at this locus.

[0210] Table 8. List of IGHV genes on mouse chromosome 12

[0211]

[0212]

[0213]

[0214] Table 9 lists all IGHD genes on mouse chromosome 12 and their relative order. Table 10 lists all IGHJ genes on mouse chromosome 12 and their relative order. Genes of the immunoglobulin constant domain follow the IGHV, IGHD, and IGHJ genes. These genes include (in the following order): immunoglobulin heavy chain constant μ (IGHM), immunoglobulin heavy chain constant δ (IGHδ), immunoglobulin heavy chain constant γ3 (IGHG3), immunoglobulin heavy chain constant γ1 (IGHG1), immunoglobulin heavy chain constant γ2b (IGHG2b), immunoglobulin heavy chain constant γ2a (IGHG2a), immunoglobulin heavy chain constant ε (IGHE), and immunoglobulin heavy chain constant α (IGHA) genes. These genes and their order are also shown in... Figure 17 and Figure 21 middle.

[0215] Table 9. List of IGHD genes on mouse chromosome 12

[0216]

[0217]

[0218] Table 10. List of IGHJ genes on mouse chromosome 12

[0219] Gene name order Gene name order IGHJ1 203 IGHJ3 205 IGHJ2 204 IGHJ4 206

[0220] This disclosure provides genetically modified non-human animals that contain one or more human IGHV genes, one or more human IGHD genes, and / or one or more human IGHJ genes.

[0221] The genetically modified animals can be prepared by introducing human immunoglobulin genes into the genome of non-human animals to produce animals capable of expressing humanized antibodies or chimeric antibodies. Figure 1A A method for preparing humanized mice is illustrated. In some embodiments, the method first involves modifying human immunoglobulin regions on a human chromosome. The modified human chromosome is then introduced into mouse recipient cells. The variable regions of human immunoglobulins are then introduced into the corresponding regions of the mouse genome via direct substitution (e.g., in a one-step substitution). Recipient cells are then screened, preferably cells that do not contain human chromosomes. The cells are then injected into blastocysts to prepare chimeric animals (e.g., mice). Subsequent breeding can be performed to obtain animals containing complete humanized immunoglobulin loci.

[0222] In some embodiments, the human IGHV gene, human IGHD gene, and human IGHJ gene are operatively linked together and are capable of VDJ rearrangement. In some embodiments, the human IGHV gene, human IGHD gene, and human IGHJ gene are located at an endogenous heavy chain immunoglobulin locus.

[0223] In some embodiments, the animal contains about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, or 161 human IGHV genes (e.g., genes as shown in Table 5).

[0224] In some embodiments, the animal contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 genes selected from IGHV(III)-82, IGHV7-81, IGHV4-80, IGHV3-79, IGHV(II)-78-1, IGHV5-78, IGHV7-77, IGHV(III)-76-1, IGHV3-76, and IGHV3-75.

[0225] In some embodiments, the animal contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 genes selected from IGHV(III)-5-2, IGHV(III)-5-1, IGHV2-5, IGHV7-4-1, IGHV4-4, IGHV1-3, IGHV(III)-2-1, IGHV1-2, IGHV(II)-1-1, and IGHV6-1.

[0226] In some embodiments, the animal comprises an unmodified human sequence comprising a sequence that begins with a gene selected from IGHV(III)-82, IGHV7-81, IGHV4-80, IGHV3-79, IGHV(II)-78-1, IGHV5-78, IGHV7-77, IGHV(III)-76-1, IGHV3-76, and IGHV3-75 and terminates with a gene selected from IGHV(III)-5-2, IGHV(III)-5-1, IGHV2-5, IGHV7-4-1, IGHV4-4, IGHV1-3, IGHV(III)-2-1, IGHV1-2, IGHV(II)-1-1, and IGHV6-1. In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from human IGHV(III)-82 to human IGHV1-2. In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from human IGHV(III)-82 to human IGHV(II)-1-1. In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from human IGHV(III)-82 to human IGHV-6-1.

[0227] In some embodiments, the animal contains about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 human IGHD genes (e.g., genes as shown in Table 6). In some embodiments, the animal contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 genes selected from IGHD1-1, IGHD2-2, IGHD3-3, IGHD4-4, IGHD5-5, IGHD4-23, IGHD5-24, IGHD6-25, IGHD1-26, and IGHD7-27.

[0228] In some embodiments, the animal contains about or at least one, two, three, four, five, six, seven, eight, or nine human IGHJ genes (e.g., genes shown in Table 7). In some embodiments, the animal includes one, two, three, four, five, six, seven, eight, or nine human IGHJ genes selected from IGHJ1P, IGHJ1, IGHJ2, IGHJ2P, IGHJ3, IGHJ4, IGHJ5, IGHJ3P, and IGHJ6.

[0229] In some embodiments, the animal comprises an unmodified human sequence comprising a sequence beginning with a gene selected from IGHD1-1, IGHD2-2, IGHD3-3, IGHD4-4, IGHD5-5, IGHD4-23, IGHD5-24, IGHD6-25, IGHD1-26, and IGHD7-27 and terminating with a gene selected from IGHJ1P, IGHJ1, IGHJ2, IGHJ2P, IGHJ3, IGHJ4, IGHJ5, IGHJ3P, and IGHJ6. In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from human IGHD1-1 to human IGHJ6.

[0230] In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from IGHD1-1 to human IGHD7-27.

[0231] In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from human IGHJ1P to human IGHJ6. In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from human IGHJ1 to human IGHJ6.

[0232] In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from human IGHV(III)-82 to human IGHJ6.

[0233] In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from human IGHV1-2 to human IGHJ6. In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from human IGHV(II)-1-1 to human IGHJ6. In some embodiments, the unmodified human sequence is derived from the portion of the human heavy chain immunoglobulin locus from human IGHV6-1 to human IGHJ6.

[0234] In some embodiments, the animal may have one, two, three, four, five, six, seven, eight, nine, or ten unmodified human sequences. In some embodiments, the length of the unmodified human sequence is approximately or at least 10kb, 20kb, 30kb, 40kb, 50kb, 60kb, 70kb, 80kb, 90kb, 100kb, 200kb, 300kb, 400kb, 500kb, 600kb, 700kb, 800kb, 900kb, or 1000kb.

[0235] In some embodiments, the animal comprises one or more endogenous genes selected from the group consisting of the genes for immunoglobulin heavy chain constant μ (IGHM), immunoglobulin heavy chain constant δ (IGHδ), immunoglobulin heavy chain constant γ3 (IGHG3), immunoglobulin heavy chain constant γ1 (IGHG1), immunoglobulin heavy chain constant γ2b (IGHG2b), immunoglobulin heavy chain constant γ2a (IGHG2a), immunoglobulin heavy chain constant ε (IGHE), and immunoglobulin heavy chain constant α (IGHA). In some embodiments, these endogenous genes are operatively linked together. In some embodiments, these endogenous genes have the same sequence as in wild-type animals. In some embodiments, isotype switching (immunoglobulin class switching) may occur in the animal.

[0236] In some embodiments, the IGHV, IGHD, and / or IGHJ genes are operatively linked together. VDJ recombination can occur between these genes and produce functional antibodies. In some embodiments, these genes are arranged in a sequence similar to that in human heavy chain immunoglobulin loci. This arrangement provides several advantages; for example, the arrangement of these genes allows for the generation of heavy chain variable domains with a diversity very similar to that in humans. Because some random sequences can be inserted into the sequence during VDJ recombination, in some embodiments, unmodified or minimally modified whole human antibody lineages can reduce the likelihood of non-human sequences being inserted during VDJ recombination.

[0237] In some embodiments, the IGHV gene, IGHD gene, and / or IGHJ gene are operatively linked together with one or more genes selected from the IGHM, IGHδ, IGHG3, IGHG1, IGHG2b, IGHG2a, IGHE, and IGHA genes (e.g., all genes).

[0238] In some embodiments, the animal includes disruption of its endogenous heavy chain immunoglobulin gene loci. In some embodiments, disruption of the endogenous heavy chain immunoglobulin gene loci in the animal includes the deletion of one or more endogenous IGHV genes, one or more endogenous IGHD genes, and one or more endogenous IGHJ genes.

[0239] In some embodiments, the animal is a mouse. Disruptions in the endogenous heavy chain immunoglobulin loci of the animal include the deletion of at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, or 182 mouse IGHV genes (e.g., genes shown in Table 8). In some embodiments, the disruption includes the deletion of about or at least one, two, three, four, five, six, seven, eight, nine, or ten mouse IGHV genes selected from IGHV1-86, IGHV1-85, IGHV1-84, IGHV1-83, IGHV1-82, IGHV1-81, IGHV1-80, IGHV1-79, IGHV1-78, and IGHV1-77. In some embodiments, the mice still include about or at least one, two, three, four, five, six, seven, eight, nine, or ten mouse IGHV genes selected from IGHV1-86, IGHV1-85, IGHV1-84, IGHV1-83, IGHV1-82, IGHV1-81, IGHV1-80, IGHV1-79, IGHV1-78, and IGHV1-77 (e.g., IGHV1-86).

[0240] In some embodiments, the disruption comprises the deletion of approximately or at least one, two, three, four, five, six, seven, eight, nine, or ten mouse IGHV genes selected from IGHV5-6, IGHV5-5, IGHV2-3, IGHV6-1, IGHV5-4, IGHV5-3, IGHV2-2, IGHV5-2, IGHV2-1, and IGHV5-1. In some embodiments, the mice still comprise the deletion of approximately or at least one, two, three, four, five, six, seven, eight, nine, or ten mouse IGHV genes selected from IGHV5-6, IGHV5-5, IGHV2-3, IGHV6-1, IGHV5-4, IGHV5-3, IGHV2-2, IGHV5-2, IGHV2-1, and IGHV5-1.

[0241] In some embodiments, disruption of the animal's endogenous heavy chain immunoglobulin loci comprises the deletion of at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mouse IGHD genes (e.g., genes shown in Table 9). In some embodiments, the disruption comprises the deletion of about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mouse IGHD genes selected from IGHD5-1, IGHD3-1, IGHD1-1, IGHD6-1, IGHD2-3, IGHD2-7, IGHD2-8, IGHD5-6, IGHD3-2, and IGHD4-1. In some embodiments, the mice still contain about or at least one, two, three, four, five, six, seven, eight, nine, or ten mouse IGHD genes selected from IGHD5-1, IGHD3-1, IGHD1-1, IGHD6-1, IGHD2-3, IGHD2-7, IGHD2-8, IGHD5-6, IGHD3-2, and IGHD4-1.

[0242] In some embodiments, the disruption comprises the deletion of about or at least one, two, three, or four mouse IGHJ genes selected from IGHJ1, IGHJ2, IGHJ3, and IGHJ4. In some embodiments, the mouse still contains about or at least one, two, three, or four mouse IGHJ genes selected from IGHJ1, IGHJ2, IGHJ3, and IGHJ4.

[0243] In some embodiments, disruption of the animal's endogenous heavy chain immunoglobulin locus includes the deletion of about or at least 500 kb, 600 kb, 700 kb, 800 kb, 900 kb, 1000 kb, 1500 kb, 2000 kb, 2500 kb, or 3000 kb of endogenous sequence.

[0244] In some implementations, the missing sequence begins with IGHV1-86 to IGHJ4, begins with IGHV1-85 to IGHJ4, begins with IGHV1-84 to IGHJ4, begins with IGHV1-83 to IGHJ4, or begins with IGHV1-82 to IGHJ4 (e.g., begins with IGHV1-85 to IGHJ4).

[0245] In some embodiments, the animal comprises about or at least one, two, three, four, five, six, seven, eight, nine, or ten sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to sequences in the human heavy chain immunoglobulin locus. In some embodiments, the sequence length is approximately or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 200 kb, 300 kb, 400 kb, 500 kb, 600 kb, 700 kb, 800 kb, 900 kb, 1000 kb, 1500 kb, 2000 kb, 2500 kb, 3000 kb, or 3500 kb. In some embodiments, the sequence begins with human IGHV(III)-82 to IGHV1-2. In some embodiments, the sequence begins with human IGHV7-81 to IGHV1-2. In some embodiments, the sequence begins with human IGHV(II)-1-1 to IGHVJ6. In some implementations, the sequence begins with human IGHV6-1 and extends to IGHVJ6.

[0246] The human IGHV, human IGHD, and human IGHJ genes are operatively linked together and are capable of VDJ rearrangement. In some embodiments, the modified mice have a complete human IGHV, IGHD, and IGHJ gene lineage (e.g., containing non-pseudogenes from all human IGHV, IGHD, and IGHJ genes). Therefore, the modified mice can generate a complete human antibody lineage.

[0247] In some implementations, the use of IGHV3-15, IGHV1-18, IGHV3-21, IGHV5-51, IGHV3-74, IGHV3-30-3, IGHV3-43, IGHV1-24, IGHV3-7, IGHV4-4, IGHV3-53, IGHV4-59, IGHV6-1, IGHV3-23, IGHV3-33, IGHV3-30, IGHV3-48, IGHV4-39, IGHV4-34, or IGHV3-66 can be detected (e.g., at a frequency of >1% among rearranged sequences). In some implementations, the use of IGHV3-38-3, IGHV1-58, IGHV4-38-2, IGHV4-61, IGHV3-NL1, IGHV2-26, IGHV1-2, IGHV7-4-1, IGHV4-28, IGHV3-64, IGHV3-49, IGHV5-10-1, IGHV3-72, IGHV2-5, IGHV2-70, IGHV1-46, IGHV1-3, IGHV3-11, IGHV3-13, IGHV3-20, IGHV3-64D, IGHV1-69, IGHV3-73, IGHV4-30-2, IGHV4-31, or IGHV4-30-4 can be detected (e.g., at a frequency of <1% between rearranged sequences).

[0248] In some implementations, the use of IGHD5-24, IGHD2-8, IGHD6-25, IGHD1-14, IGHD4-23, IGHD3-16, IGHD1-20, IGHD2-15, IGHD2-21, IGHD1-1, IGHD5-12, IGHD3-22, IGHD7-27, IGHD4-11, IGHD3-9, IGHD3-3, IGHD2-2, IGHD5-18, IGHD4-17, IGHD3-10, IGHD6-6, IGHD1-26, IGHD1-7, IGHD6-19, or IGHD6-13 can be detected (e.g., at a frequency >1% between rearranged sequences).

[0249] In some implementations, the use of IGHJ1, IGHJ2, IGHJ3, IGHJ4, IGHJ5, or IGHJ6 can be detected (e.g., at a frequency of >1% between rearranged sequences).

[0250] In some implementations, the use of IGHV1-24, IGHV4-30-2, IGHV1-18, IGHV3-43, IGHV4-30-4, IGHV5-51, IGHV3-21, IGHV4-31, IGHV3-7, IGHV3-30-3, IGHV3-53, IGHV4-4, IGHV3-74, IGHV3-66, IGHV3-33, IGHV3-23, IGHV6-1, IGHV3-30, IGHV4-34, IGHV3-48, IGHV4-59, or IGHV4-39 can be detected (e.g., at a frequency of >1% among rearranged sequences).

[0251] In some implementations, the use of IGHV3-25, IGHV4-38-2, IGHV7-4-1, IGHV3-NL1, IGHV4-61, IGHV1-58, IGHV2-26, IGHV3-72, IGHV5-10-1, IGHV1-46, IGHV3-49, IGHV2-70, IGHV1-2, IGHV3-64, IGHV4-28, IGHV3-20, IGHV1-3, IGHV3-13, IGHV3-73, IGHV3-11, IGHV3-64D, IGHV1-69, IGHV2-5, or IGHV3-15 can be detected (e.g., at a frequency of <1% among rearranged sequences).

[0252] Furthermore, because V(D)J recombination can occur between endogenous IGHV, IGHD, IGHJ, IGKV, and IGKJ genes and human genes, if these genes are integrated into rearranged heavy chain VDJ segments or rearranged light chain VJ segments, antibodies generated by the aforementioned antibody lineage are likely to possess immunogenic epitopes in humans. This immunogenicity can lead to the production and activity of anti-drug antibodies. Here, in some embodiments, the endogenous IGHV, IGHD, IGHJ, IGKV, and IGKJ genes have been effectively deleted. In some cases, the entire mouse IGHV, IGHD, and IGHJ genes (e.g., including all non-pseudogenes) are knocked out, and the heavy chain variable region will not have any sequence encoded by mouse-derived sequences.

[0253] Antibodies generated from the aforementioned antibody lineage are unlikely to be immunogenic in humans. Therefore, these antibodies are more suitable for use as therapeutic agents in humans. Thus, genetically modified animals provide a favorable platform for the production of humanized antibodies. Genetically modified λ light chain immunoglobulin locus

[0254] The λ chain immunoglobulin locus (also known as IGL or immunoglobulin λ locus) is a region on a chromosome (e.g., human chromosome 22) containing genes for the light chains of human antibodies (or immunoglobulins). Similarly, immunoglobulin light chain genes can undergo a series of rearrangements leading to the production of mature immunoglobulin light chain nucleic acids (e.g., the λ chain). In healthy individuals, the total κ ​​to λ ratio in serum is approximately 2:1 (measured with intact, complete antibodies), or 1:1.5 if free light chains are measured. In mice, the total κ ​​to λ ratio is approximately 9:1.

[0255] In some embodiments, the animal contains the human λ chain immunoglobulin locus.

[0256] In some embodiments, the animal includes disruption of an endogenous λ light chain immunoglobulin gene locus. In some embodiments, disruption of the endogenous light chain immunoglobulin gene locus includes the deletion of one or more endogenous IGLV genes, one or more endogenous IGLJ genes, and / or one or more immunoglobulin λ constant (IGLC) genes (e.g., IGLC1, IGLC2, IGLC3, and IGLC4).

[0257] The mouse λ light chain immunoglobulin locus (IGL locus) is located on mouse chromosome 16. Table 11 lists the IGLV, IGLJ, and IGLC genes and their relative order at this locus.

[0258] Table 11. List of genes at the mouse IGL locus

[0259]

[0260] The disruption in the endogenous λ light chain immunoglobulin gene loci of the animal comprises the deletion of at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 mouse IGLV, IGLJ, and IGLC genes (e.g., genes shown in Table 11). In some embodiments, the deletion comprises about or at least 1, 2, 3, or 4 mouse IGLC genes selected from IGLC1, IGLC2, IGLC3, and IGLC4. In some embodiments, the disruption comprises the deletion of about or at least 1, 2, or 3 mouse IGLV genes selected from IGLV1, IGLV2, and IGLV3. In some embodiments, the disruption comprises the deletion of about or at least 1, 2, 3, 4, or 5 mouse IGLJ genes selected from IGLJ1, IGLJ2, IGLJ3, IGLJ3P, and IGLJ4.

[0261] In some embodiments, the disruption in the endogenous λ light chain immunoglobulin locus of the animal comprises the deletion of about or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 110 kb, 120 kb, 130 kb, 140 kb, 150 kb, 160 kb, 170 kb, 180 kb, 190 kb, 200 kb, 210 kb, 220 kb, 230 kb, 240 kb, 250 kb, 260 kb, 270 kb, 280 kb, 290 kb, 300 kb, 350 kb, 400 kb, 450 kb, 500 kb, or 1000 kb of nucleotides. In some embodiments, the endogenous λ light chain immunoglobulin gene in the animal is not disrupted.

[0262] In some implementations, the missing sequence begins from IGLV2 to IGLC1, from IGLV3 to IGLC1, or from IGLJ2 ​​to IGLC1.

[0263] For a detailed description of genetically modified animals and genetically modified heavy chain immunoglobulin loci, see, for example, PCT / CN 2020 / 075698, which is incorporated herein by reference in its entirety.

[0264] Genetically modified animals

[0265] In one aspect, this disclosure provides genetically modified non-human animals comprising humanized light chain immunoglobulin loci and / or humanized heavy chain immunoglobulin loci. The humanized light chain immunoglobulin loci comprise a limited set of human IGKV genes and / or human IGKJ genes. In some embodiments, these genes are located in endogenous immunoglobulin loci.

[0266] In some embodiments, the animal contains a human λ chain immunoglobulin locus. In some embodiments, the animal contains disruption of an endogenous λ light chain immunoglobulin locus. In some embodiments, the animal does not contain disruption of an endogenous λ light chain immunoglobulin locus.

[0267] The genetically modified non-human animal can be any animal, such as a mouse, rat, rabbit, pig, cattle (e.g., cow, bull, buffalo), deer, sheep, goat, chicken, cat, dog, ferret, or primate (e.g., marmoset, rhesus monkey). For non-human animals from which suitable genetically modified embryonic stem (ES) cells are not readily available, other methods can be used to prepare genetically modified non-human animals. Such methods include, for example, modifying the genome of a non-ES cell (e.g., fibroblasts or induced pluripotent cells), transferring the modified genome to a suitable cell, such as an oocyte, using nuclear transfer, and gestating the modified cell (e.g., the modified oocyte) in a non-human animal under suitable conditions to form an embryo. These methods are known in the art and are described, for example, in Nagy et al., “Manipulating the Mouse Embryo: A Laboratory Manual (3rd Edition),” Cold Spring Harbor Laboratory Press, 2003 (which is incorporated herein by reference in its entirety). Therefore, in various implementations, human V, D, and / or J segments can be operatively linked to non-human animal (e.g., rodent, mouse, rat, hamster) constant region gene sequences. During B cell development, these rearranged human V, D, and / or J segments are linked to non-human animal immunoglobulin constant regions.

[0268] In one aspect, the animal is a mammal, for example, a mammal belonging to the superfamily Diplodocoidea or Muridae. In some embodiments, the genetically modified animal is a rodent. The rodent may be selected from mice, rats, and hamsters. In some embodiments, the genetically modified animal is selected from the families Calomyscidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamsters, New World rats and mice, voles), Muridae (mice and rats, gerbils, spiny mice, crested rats), Nesomyidae (climbing mice, rock mice, white-tailed rats, Madagascar rats and mice), Platacanthomyidae (e.g., spiny dormice), and Spalacidae (e.g., moles, bamboo rats, and voles). In some embodiments, the genetically modified rodent is selected from mice or rats (Muscidae), gerbils, spiny mice, and crested rats. In some embodiments, the non-human animal is a mouse.

[0269] In some embodiments, the animal is a C57 background mouse (e.g., a C57BL strain selected from C57BL / A, C57BL / An, C57BL / GrFa, C57BL / KaLwN, C57BL / 6, C57BL / 6J, C57BL / 6ByJ, C57BL / 6NJ, C57BL / 10, C57BL / 10ScSn, C57BL / 10Cr, and C57BL / Ola). In some embodiments, the mice are 129 strains selected from the group consisting of strains 129P1, 129P2, 129P3, 129X1, 129S1 (e.g., 129S1 / SV, 129S1 / SvIm), 129S2, 129S4, 129S5, 129S9 / SvEvH, 129S6 (129 / SvEvTac), 129S7, 129S8, 129T1, and 129T2. These mice are described, for example, in Festing et al., Revised nomenclature for strain 129 mice, Mammalian Genome 10:836 (1999); Auerbach et al., Establishment and Chimera Analysis of 129 / SvEv-and C57BL / 6-Derived Mouse Embryonic Stem Cell Lines (2000), both of which are incorporated herein by reference in their entirety. In some embodiments, the genetically modified mouse is a cross between the 129 strain and the C57BL / 6 strain. In some embodiments, the mouse is a cross between the 129 strain or the BL / 6 strain. In some embodiments, the mouse is a BALB strain, such as the BALB / c strain. In some embodiments, the mouse is a cross between the BALB strain and another strain. In some implementations, the mice are derived from hybrid strains (e.g., 50% BALB / c-50% 12954 / Sv; or 50% C57BL / 6-50% 129).

[0270] In some embodiments, the animal is a rat. The rat may be selected from Wistar rats, the LEA strain, the Sprague Dawley strain, the Fischer strain, F344, F6, and Dark Agouti. In some embodiments, the rat strain is a hybrid strain selected from two or more strains of the group consisting of Wistar, LEA, Sprague Dawley, Fischer, F344, F6, and Dark Agouti.

[0271] The animal may have one or more other genetic modifications and / or other modifications suitable for the specific purpose of producing a humanized animal.

[0272] Genetically modified nonhuman animals comprising modifications to endogenous nonhuman immunoglobulin loci. In some embodiments, the modification may comprise at least a portion of a human protein encoding a human nucleic acid sequence (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a human heavy chain variable domain or light chain variable domain sequence). Although genetically modified cells (e.g., ES cells, somatic cells) that may comprise the modifications described herein are also provided, in many embodiments, the genetically modified nonhuman animals comprise modifications to endogenous loci in an animal germline.

[0273] Genetically modified animals can express humanized antibodies and / or chimeric antibodies derived from endogenous mouse loci, wherein one or more endogenous mouse immunoglobulin genes have been replaced with human immunoglobulin genes and / or nucleotide sequences, said nucleotide sequences being at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to human immunoglobulin gene sequences (e.g., IGHV, IGHD, IGHJ, IGKV, and / or IGKJ genes). In various embodiments, the endogenous non-human immunoglobulin loci are modified, either entirely or partially, to contain human nucleic acid sequences.

[0274] Genetic, molecular, and behavioral analyses can be performed on the aforementioned non-human mammals. This disclosure also relates to offspring produced by mating a non-human mammal provided herein with a mammal of the same genotype or other genotypes. The non-human mammal can be any non-human animal known in the art and can be used in the methods described herein. Preferred non-human mammals are mammals (e.g., rodents). In some embodiments, the non-human mammal is a mouse.

[0275] This disclosure also provides cell lines or primary cell cultures derived from non-human mammals or their offspring. Cell culture-based models can be prepared, for example, by methods such as isolation from non-human mammals, or by obtaining cells from cell cultures established using the same constructs and standard cell transfection techniques. Integration of genetic constructs containing DNA sequences encoding human or humanized immunoglobulins can be detected by various methods.

[0276] Numerous analytical methods are available for detecting exogenous DNA or modifications to genomic DNA, including methods at the nucleic acid level (such as mRNA quantification using reverse transcription polymerase chain reaction (RT-PCR) or Southern blotting and in situ hybridization) and methods at the protein level (such as histochemistry, immunoblotting, and in vitro binding studies). Additionally, the expression level of a target gene can be quantified using ELISA techniques well-known to those skilled in the art. Many standard analytical methods are available for performing quantitative measurements. For example, transcriptional levels can be measured using RT-PCR and hybridization methods including ribonuclease protection, Southern blotting, and RNA dot analysis. Immunohistochemical staining, flow cytometry, and Western blotting can also be used to assess the presence of human or humanized proteins.

[0277] Antibody and antigen binding fragment

[0278] This disclosure provides antibodies and their antigen-binding fragments (e.g., humanized antibodies or chimeric antibodies) generated by methods as described herein.

[0279] Typically, antibodies (also known as immunoglobulins) consist of two types of polypeptide chains: light chains and heavy chains. The non-limiting antibody disclosed herein can be an antibody comprising all four immunoglobulin chains, including two heavy chains and two light chains. The heavy chain of the antibody can be any isotype or subclass, where the isotype includes IgM, IgG, IgE, IgA, or IgD, and the subclass includes IgG1, IgG2, IgG2a, IgG2b, IgG3, IgG4, IgE1, IgE2, etc. The light chain can be a κ light chain or a λ light chain. The antibody can contain two identical copies of the light chain and two identical copies of the heavy chain. Each contains a variable domain (or variable region, V...). H The two heavy chains, consisting of a 5-chain structure and multiple constant domains (or constant regions), are linked together via disulfide bonds within their constant domains to form the "stem" of the antibody. Each chain contains a variable domain (or variable region, V0). L Each of the two light chains, each containing a constant structural domain (or constant region), is bonded to a heavy chain via a disulfide bond. The variable regions of each light chain pair with the variable regions of the heavy chain to which it is bonded. Both the light and heavy chain variable regions contain three highly variable regions sandwiched between more conservative framework regions (FRs).

[0280] These hypervariable regions (called complementarity-determining regions (CDRs)) form a loop containing the antibody's primary antigen-binding surface. The four framework regions primarily adopt a β-sheet conformation, and the CDRs form loops connecting the β-sheet structures, and in some cases, these loops form part of the β-sheet structure. The CDRs in each chain are closely adjacent through the framework regions and, together with CDRs from other chains, form the antigen-binding region.

[0281] Identifying the CDR region of an antibody by analyzing its amino acid sequence is a well-known method, and many definitions of CDR are commonly used. The Kabat definition is based on sequence variability, while the Chothia definition is based on the location of the structural loop region. These methods and definitions are described in, for example, Martin, “Protein sequence and structure analysis of antibody variable domains”, Antibody Engineering, Springer Berlin Heidelberg, 2001. 422-439; Abhinandan et al., “Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains”, Molecular Immunology 45.14(2008):3832-3839; Wu, TT and Kabat, EA (1970) J. Exp. Med. 132:211-250; Martin et al., Methods Enzymol. 203:121-53 (1991); Morea et al., Biophys Chem. 68(1-3):9-16 (October 1997); Morea et al., J Mol Biol. 275(2):269-94 (January 1998); Chothia et al., Nature 342(6252):877-83 (December 1989); Ponomarenko and Bourne, BMC Structural Biology 7:64 (2007); All references are included in this paper in their full text by citation.

[0282] CDRs are important for recognizing antigenic epitopes. As used in this article, an "epitaph" is the smallest part of a target molecule that can be specifically bound by the antigen-binding domain of an antibody. The smallest size of an epitope may be about three, four, five, six, or seven amino acids, but these amino acids do not necessarily have to be located in a continuous linear sequence of the primary structure of the antigen, as the epitope may depend on the three-dimensional conformation of the antigen based on its secondary and tertiary structures.

[0283] In some implementations, antibodies are intact immunoglobulin molecules (e.g., IgG1, IgG2a, IgG2b, IgG3, IgG4, IgM, IgD, IgE, IgA). IgG subclasses (IgG1, IgG2, IgG3, and IgG4) are highly conserved, differing primarily in their constant regions, particularly their hinges and upper CH2 domains. The sequences and differences among IgG subclasses are known in the art and described in, for example, Vidarsson et al., “IgG subclasses and allotypes: from structure to effector functions.” Frontiers in Immunology 5 (2014); Irani et al., “Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.” Molecular Immunology 67.2 (2015):171-182; Shakib, Farouk, ed., The human IgG subclasses: molecular analysis of structure, function, and regulation. Elsevier, 2016; each reference is incorporated into this paper in its full form via citation.

[0284] Antibodies can also be immunoglobulin molecules derived from any species (e.g., humans, rodents, mice, rats, camels). The antibodies disclosed herein also include, but are not limited to, polyclonal antibodies, monoclonal antibodies, monospecific antibodies, multispecific antibodies, and chimeric antibodies including an immunoglobulin-binding domain fused to another polypeptide. The term "antigen-binding domain" or "antigen-binding fragment" refers to the portion of an antibody that retains the specific binding activity of the intact antibody; that is, any portion of the antibody capable of specifically binding to an epitope on the target molecule of the intact antibody. This includes, for example, Fab, Fab', F(ab')2, and variants of these fragments. Thus, in some embodiments, an antibody or its antigen-binding fragment can be, for example, scFv, Fv, Fd, dAb, bispecific antibodies, bispecific scFv, biantibodies, linear antibodies, single-chain antibody molecules, multispecific antibodies formed from antibody fragments, and any polypeptide including a binding domain that is an antibody-binding domain or homologous to it. Non-limiting embodiments of the antigen-binding domain include, for example, the heavy chain and / or light chain CDR of an intact antibody, the heavy chain and / or light chain variable region of an intact antibody, the full-length heavy chain or light chain of an intact antibody, or a separate CDR derived from the heavy chain or light chain of an intact antibody.

[0285] In some embodiments, the antigen-binding fragment may form part of a chimeric antigen receptor (CAR). In some embodiments, the chimeric antigen receptor is a fusion of a single-stranded variable fragment (scFv) as described herein with the CD3-ζ transmembrane domain and inner domain.

[0286] In some embodiments, the scFV has one heavy chain variable domain and one light chain variable domain. In some embodiments, the scFV has two heavy chain variable domains and two light chain variable domains. In some embodiments, the scFV has two antigen-binding regions, and the two antigen-binding regions can bind their respective target antigens.

[0287] Antibodies and their antigen-binding fragments (e.g., humanized or chimeric antibodies) generated by the methods described herein have various advantages. In some embodiments, further optimization is not required to obtain the desired properties (e.g., binding affinity, thermal stability, and / or limited aggregation).

[0288] In some embodiments, the antibody (or its antigen-binding fragment) specifically binds to the target, wherein the dissociation rate (koff) is less than 0.1 s. -1 Less than 0.01s -1 Less than 0.001s -1 Less than 0.0001s -1 Or less than 0.00001s -1 In some implementations, the dissociation rate (koff) is greater than 0.01 s.-1 Greater than 0.001s -1 Greater than 0.0001s -1 Greater than 0.00001s -1 or greater than 0.000001s -1 In some implementations, the majority (e.g., >50%, >60%, >70%, or >80%) of these antibodies have a koff of 1×10⁻⁶. -2 / S and 1×10 -3 Between / S.

[0289] In some implementations, the association rate (kon) is greater than 1 x 10⁻⁶. 2 / Ms, greater than 1x 10 3 / Ms, greater than 1x10 4 / Ms, greater than 1x 10 5 / Ms or greater than 1x 10 6 / Ms. In some implementations, the association rate (kon) is less than 1 x 10 5 / Ms, less than 1x 10 6 / Ms or less than 1x 10 7 / Ms. In some embodiments, the majority (e.g., >50%, >60%, >70%, or >80%) of these antibodies have a kon value of 1×10 5 / Ms and 1×10 6 Between / Ms.

[0290] The affinity can be derived from the quotient of the kinetic rate constant (KD = koff / kon). In some implementations, KD is less than 1 x 10⁻⁶. -6 M, less than 1 x 10 -7 M, less than 1 x 10 -8 M, less than 1 x 10 -9 M or less than 1x10 -10 M. In some implementations, KD is less than 50 nM, 40 nM, 30 nM, 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM. In some implementations, KD is greater than 1 x 10^6 nM. -7 M, greater than 1 x 10 -8 M, greater than 1 x 10 -9 M, greater than 1 x 10 -10 M, greater than 1 x 10 -11 M, or greater than 1 x 10 -12M. In some embodiments, the antibody binds to a target with a KD less than or equal to about 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM. In some embodiments, a majority (e.g., >50%, >60%, >70%, or >80%) of these antibodies have a KD between 0.10 nM and 100.00 nM (e.g., between 1 nM and 100 nM).

[0291] In some embodiments, the median heavy chain CDR3 length of the antibodies produced by animals, as described herein, is 13-15 amino acids. In some embodiments, the majority (e.g., >50%, >60%, >70%, or >80%) of these antibodies have a heavy chain CDR3 length between 9 and 18 amino acids, or between 10 and 17 amino acids.

[0292] In some embodiments, as described herein, less than 30%, 20%, or 15% of the heavy chain CDR3 in the animal-derived antibodies have cysteine ​​residues (e.g., one or two cysteine ​​residues). In some embodiments, the heavy chain CDR3 has no more than 21 amino acid residues.

[0293] In some implementations, thermal stability has been determined. The antibody or antigen-binding fragments described herein may have a Tm greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, or 95°C.

[0294] Because IgG can be described as a multidomain protein, melting curves sometimes show two or three transitions, with a first denaturation temperature TmD1, a second denaturation temperature TmD2, and optionally a third denaturation temperature TmD3.

[0295] In some embodiments, the antibody or antigen-binding fragment as described herein has a Tm D1 greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, or 95°C. In some embodiments, the antibody or antigen-binding fragment as described herein has a Tm D2 greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, or 95°C. In some embodiments, the antibody or antigen-binding fragment as described herein has a Tm D3 greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, or 95°C.

[0296] In some implementations, Tm, TmD1, TmD2, and TmD3 are less than 60℃, 61℃, 62℃, 63℃, 64℃, 65℃, 66℃, 67℃, 68℃, 69℃, 70℃, 71℃, 72℃, 73℃, 74℃, 75℃, 76℃, 77℃, 78℃, 79℃, 80℃, 81℃, 82℃, 83℃, 84℃, 85℃, 86℃, 87℃, 88℃, 89℃, 90℃, 91℃, 92℃, 93℃, 94℃, or 95℃.

[0297] In some implementations, when the temperature is below 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, or 95°C, the antibody or antigen-binding fragments described herein do not aggregate.

[0298] Methods for preparing genetically modified animals

[0299] The genetically modified animals can be prepared by introducing human immunoglobulin genes into the genome of non-human animals to produce animals capable of expressing humanized antibodies or chimeric antibodies. Figure 1A A method for preparing humanized animals is illustrated. In some embodiments, the method first involves modifying human immunoglobulin loci on a human chromosome. The modified human chromosome is then introduced into mouse recipient cells. The variable regions of human immunoglobulins are then introduced into the corresponding regions of the mouse genome via direct substitution. The recipient cells are then screened. In some embodiments, the cells do not contain human chromosomes. The cells are then injected into blastocysts to prepare chimeric mice. Subsequent breeding can be performed to obtain mice containing complete humanized immunoglobulin loci.

[0300] Several other techniques can also be used to produce genetically modified animals, including, for example, non-homologous end joining (NHEJ), homologous recombination (HR), zinc finger nucleases (ZFN), transcription activator-like effector-based nucleases (TALEN), and the regular family-interval short palindromic repeat (CRISPR)-Cas system. In some embodiments, homologous recombination is used. In some embodiments, CRISPR-Cas9 genome editing is used to produce genetically modified animals. Many of these genome editing techniques are known in the art and described, for example, in Yin et al., “Delivery technologies for genome editing,” Nature Reviews Drug Discovery 16.6 (2017):387-399, which is incorporated herein by reference in its entirety. Many other methods are also provided, and these methods can be used for genome editing, such as microinjecting genetically modified cell nuclei into enucleated oocytes and fusing enucleated oocytes with another genetically modified cell.

[0301] Genetic modification processes can involve replacing endogenous sequences with human sequences via homologous recombination. In some implementations, upstream and downstream cuts at the target site (e.g., via zinc finger nucleases, TALEN, or CRISPR) can cause DNA double-strand breaks, and homologous recombination is used to replace endogenous sequences with human sequences.

[0302] In some embodiments, methods for preparing genetically modified humanized animals may include the step of replacing nucleic acids (e.g., V, D, J regions or V, J regions) at an endogenous gene locus (or site) with a corresponding region of a human sequence. The sequence may contain regions (e.g., a portion or the entire region) of the IGHV, IGHD, IGHJ, IGKV, and / or IGKJ genes. In some embodiments, the substitution is mediated by homologous recombination. In some embodiments, the substitution is mediated by Cre recombinase.

[0303] In some embodiments, modification of the mouse light chain immunoglobulin gene locus can be performed directly. In some embodiments, the vector is used directly to replace the entire variable region of the mouse light chain immunoglobulin. In some embodiments, the vector can be inserted upstream of the V region and between the J and C regions.

[0304] In some embodiments, modification of the mouse light chain immunoglobulin locus can be performed in more than one step. In some embodiments, a first vector can be used to replace the entire variable region of the mouse light chain immunoglobulin. In some embodiments, the vector contains one or more selection markers. In some embodiments, the selection marker is a dominant selection marker (e.g., a neomycin resistance gene or Neo). In some embodiments, the selection marker is a negative selection marker (e.g., a diphtheria toxin receptor gene or DTR). In some embodiments, the first vector contains one or more dominant selection markers and / or one or more negative selection markers. As described herein, in some embodiments, a second vector can be used to further replace the region containing one or more selection markers.

[0305] Figure 4This paper illustrates a targeting strategy for replacing the variable region of endogenous mouse light chain immunoglobulins with the variable region of human light chains (e.g., rearranged or unrearranged human light chain variable region sequences). For example, the human light chain variable region may contain human IGKV genes selected from IGKV3-20, IGKV3-11, and IGKV1-39; and human IGKJ genes selected from IGKJ1 and IGKJ4. In some embodiments, the entire mouse light chain variable region is replaced by a first vector containing Neo and DTR selection marker genes. In some embodiments, the second vector has one or more of the following from 5' to 3': a DNA homologous arm sequence upstream of the insertion site (5' homologous arm); a promoter sequence preceding the first nucleotide of the human IGKV gene (e.g., at least or about 2000 bp preceding the human IGKV gene); the human IGKV gene (e.g., IGKV3-20, IGKV3-11, or IGKV1-39); the human IGKJ gene (e.g., IGKJ1 or IGKJ4); an auxiliary sequence (e.g., a polyA sequence, a WPRE sequence, or a 3' UTR sequence); and a DNA homologous arm sequence downstream of the insertion site (3' homologous arm).

[0306] These vectors can be integrated into the cell's genome, and cells can be selected using drug resistance markers or combinations thereof (e.g., bleomycin, G418, and / or puromycin). In some embodiments, PB transposases are expressed, and genetic elements between the transposase target sequences can be deleted.

[0307] In some embodiments, these vectors are integrated into the modified human chromosome. The human chromosome may be modified before the first and second vectors are integrated into the genome. In some embodiments, one or more additional vectors may be added at different locations on the chromosome as needed. In some embodiments, the vector is added between the C region and the centromere.

[0308] Human chromosomes can be obtained from human cell lines, cancer cells, primary cell cultures, and / or human fibroblasts. In some embodiments, a first vector is introduced into human cells, which are then fused with recipient cells. The modified chromosome is then isolated and introduced into another suitable recipient cell. Cells with desired resistance are selected to obtain cells containing only one human chromosome. A second vector is then introduced into the cells, and cells are selected by resistance. A third and / or fourth vector may then be introduced if desired. Recipient cells can be mammalian cells, human cells, or mouse cells. In some embodiments, recipient cells are CHO cells, or preferably A9 cells. In some embodiments, the modified chromosome is fluorescently labeled and isolated. The modified chromosome is then injected into the recipient cells via chromosome microinjection. In some embodiments, donor cells are induced to multinucleate their chromosomes. These nuclei are then forced to cross the cell membrane to form microcells, which can be fused with recipient cells. In some embodiments, microcell-mediated chromosome transfer may also be used. Chromosome manipulation techniques are described in, for example, CN 1200014 A, CN 109837307 A, US 20120093785A1 and US 2009253902; Kuroiwa et al., “Manipulation of human minichromosomes to carry greater than megabase-sized chromosome inserts.” Nature Biotechnology 18.10(2000):1086-1090; Chinese patent CN 1717483 A; Paulis, Marianna. “Chromosome Transfer Via Cell Fusion.” Methods in Molecular Biology 738(2011):57; Genes, Chromosomes & Cancer 14:126127(1995); Tomizuka et al., “Functional expression and germline a transmission of a human chromosome fragment in chimaeric mice.” Nature Genetics 16.2(1997):133-143; Somatic Cell and Molecular Genetics, Vol. 13, No. 3, 1987, pp. 279-284; each of these articles is incorporated into this paper in its entirety through citation.

[0309] LoxP recognition sequences can also be added to human chromosomes (e.g., human chromosomes 2, 14, and 22). Cells can also be treated with Cre enzymes, causing recombination at loxP sites, thereby removing genomic DNA sequences. In some embodiments, spontaneous chromosome breakage can also be used to remove genomic DNA sequences.

[0310] Mouse immunoglobulin variable regions can be replaced by human immunoglobulin variable regions via substitution (e.g., homologous recombination or Cre-mediated recombination). In some embodiments, Cre recombination can be used to mediate substitution. In some embodiments, the vector can add a LoxP recognition sequence to a human chromosome. Similar modifications can be made to mouse chromosomes, wherein two LoxP recognition sequences can be added to the chromosome. For example, Cre recombinase can mediate the substitution of mouse chromosome V and J regions with human chromosome V and J regions, or the substitution of mouse chromosome V, D, and J regions with human chromosome V, D, and J regions.

[0311] Cells lacking human chromosomes can be further screened (e.g., by DT). In some cases, cells not screened by DT may contain recombinant human chromosome fragments, but these fragments are small and unstable in mouse cells (e.g., Shinohara et al. (2000) Chromosome Research, 8:713-725) and disappear spontaneously during cell proliferation. In some embodiments, large segments of modified human chromosomes are deleted, for example, through Cre-mediated deletion or through spontaneous chromosome breakage.

[0312] The 5' terminal homologous arm and / or the 3' terminal homologous arm may have a desired length to facilitate homologous recombination. In some embodiments, the homologous arm is about 1 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 7 kb, 8 kb, 9 kb, 10 kb, 20 kb, 30 kb, 40 kb, or 50 kb (e.g., about 3 kb). In some embodiments, the homologous arm is less than 1 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 7 kb, 8 kb, 9 kb, 10 kb, 20 kb, 30 kb, 40 kb, or 50 kb.

[0313] In some embodiments, the vector may optionally contain a reporter protein, such as a luciferase (e.g., Gluc) or a fluorescent protein (e.g., EGFP, BFP, etc.).

[0314] These modifications can be performed in various cells. In some implementations, the cells are stem cells, embryonic stem cells, or fertilized egg cells.

[0315] This disclosure also provides a method for establishing humanized animal models, the method comprising the following steps:

[0316] (a) Providing cells (e.g., fertilized egg cells) based on the methods described herein;

[0317] (b) Culture the cells in a liquid culture medium;

[0318] (c) Transplanting the cultured cells into the fallopian tubes or uterus of a recipient female non-human mammal, allowing the cells to develop in the uterus of the female non-human mammal.

[0319] (d) Identify the phylogenetic spread of the offspring of the pregnant female in genetically modified humanized non-human mammals in step (c).

[0320] In some implementations, the non-human mammal in the aforementioned method is a mouse (e.g., a C57 mouse, a BALB / c mouse, or a C57BL / 6 mouse).

[0321] In some implementations, the non-human mammal in step (c) is a female animal that is experiencing pseudopregnancy (or false pregnancy).

[0322] In some embodiments, the fertilized egg used in the above method is a C57BL / 6 fertilized egg. Other fertilized eggs that can also be used as described herein include, but are not limited to, FVB / N fertilized eggs, BALB / c fertilized eggs, DBA / 1 fertilized eggs, and DBA / 2 fertilized eggs.

[0323] The fertilized egg can be derived from any non-human animal, such as any non-human animal described herein. In some embodiments, the fertilized egg cell is derived from a rodent. Gene constructs can be introduced into the fertilized egg via microinjection of DNA. For example, by culturing the fertilized egg after microinjection, the cultured fertilized egg can be transferred to a pseudopregnant non-human animal, which then produces a non-human mammal, thereby generating the non-human mammal mentioned in the above methods.

[0324] Cells, tissues, and animals (e.g., mice) containing nucleotide sequences as described herein, as well as cells, tissues, and animals (e.g., mice) expressing humanized or chimeric antibodies derived from endogenous nonhuman loci, are also provided.

[0325] This disclosure also provides various targeting vectors (e.g., vectors for preparing genetically modified animals). In some embodiments, the vector may comprise: a) a DNA fragment homologous to the 5' end of the region to be modified (5' homologous arm); b) a sequence containing the desired genetic element (e.g., a LoxP recognition site, a drug resistance gene, and / or a reporter gene, etc.); and c) a second DNA fragment homologous to the 3' end of the region to be modified (3' homologous arm). This disclosure also relates to cells comprising targeting vectors as described herein.

[0326] In some embodiments, the genes in the cell are heterozygous. In some embodiments, the genes in the cell are homozygous.

[0327] In some embodiments, the non-human mammalian cell is a mouse cell. In some embodiments, the cell is a fertilized egg cell.

[0328] This disclosure also relates to methods for generating genetically modified animal models having two or more individual or chimeric genes. The animals may comprise one or more human or humanized immunoglobulin loci and sequences encoding additional human or chimeric proteins. In some embodiments, the additional human or chimeric protein may be programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte activation 3 (LAG-3), B and T lymphocyte-associated protein (BTLA), programmed cell death 1 ligand 1 (PD-L1), CD27, CD28, CD47, CD137, CD154, T-cell immune receptor with Ig and ITIM domains (TIGIT), T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), glucocorticoid-induced TNFR-associated protein (GITR), or TNF receptor superfamily member 4 (TNFRSF4 or OX40).

[0329] Methods for generating genetically modified animal models with additional human or chimeric genes (e.g., humanized genes) may include the following steps:

[0330] (a) Obtaining genetically modified nonhuman animals using the methods described herein;

[0331] (b) Mating the genetically modified nonhuman animal with another genetically modified nonhuman animal and then screening offspring to obtain genetically modified nonhuman animals with two or more individual or chimeric genes.

[0332] In some embodiments, in step (b) of the method, the genetically modified animal may be mated with a genetically modified non-human animal having human or chimeric PD-1, CTLA-4, LAG-3, BTLA, PD-L1, CD27, CD28, CD47, CD137, CD154, TIGIT, TIM-3, GITR, SIRPa, or OX40. For example, some of these genetically modified nonhuman animals are described in PCT / CN 2017 / 090320, PCT / CN2017 / 099577, PCT / CN 2017 / 099575, PCT / CN 2017 / 099576, PCT / CN 2017 / 099574, PCT / CN2017 / 106024, PCT / CN 2017 / 110494, PCT / CN 2017 / 110435, PCT / CN 2017 / 120388, PCT / CN2018 / 081628, and PCT / CN 2018 / 081629; each of these is incorporated herein by reference in its entirety.

[0333] This disclosure further relates to methods for generating knockout animals. In some embodiments, if an animal (e.g., a mouse) expresses a protein very similar to a target antigen, it may be difficult to elicit an immune response in the animal. This is because, during immune cell development, B cells and T cells that recognize MHC molecules that bind to self-derived peptides are removed from the immune cell lineage. In these cases, the genetically engineered animal can be further modified. The corresponding gene can be knocked out in the animal, and then the animal is exposed to the target antigen. Because the animal does not negatively select for the gene product, it can produce antibodies that can readily bind specifically to the target. Therefore, in some embodiments, this disclosure also provides methods for knocking out a target gene in a genetically modified animal. In some embodiments, the gene can be knocked out using various known gene-editing techniques, such as the CRISPR-Cas system, TALEN, or ZFN. In some embodiments, the genetically modified animal can be mated with another animal whose target gene has been knocked out. Once an animal with a knockout phenotype is created, the animal can be exposed to the target antigen to produce antibodies (e.g., antibodies with a shared light chain). In some embodiments, the target antigen is a human protein. In some implementations, the target antigen is PD-1, CTLA-4, LAG-3, BTLA, PD-L1, CD27, CD28, CD47, CD137, CD154, TIGIT, TIM-3, GITR, SIRPa, or OX40.

[0334] In some embodiments, the genetically modified animal may possess the human ADAM6 gene, an endogenous ADAM6 gene, or a modified ADAM6 gene (e.g., at its endogenous locus). The ADAM6 protein is a member of the ADAM protein family, where ADAM is an acronym for integrin and metalloproteinase. The human ADAM6 gene, typically found between IGHV 1-2 and IGHV 6-1 in the human IGHV gene, is a pseudogene. Figure 16 In mice, there are two ADAM6 genes, ADAM6a and ADAM6b. They are located in the intergenic region between the mouse IGHV and IGHD gene clusters. Mouse ADAM6a is located between mouse IGHV5-1 and mouse IGHD5-1. Mouse ADAM6b is located between mouse IGHD3-1 and mouse IGHD1-1. Therefore, in some embodiments, the genetically modified animal may possess the human ADAM6 gene. In some embodiments, the genetically modified animal does not possess the endogenous ADAM6 gene.

[0335] In some embodiments, the genetically modified animal is a mouse. In some embodiments, the mouse is modified to include a nucleotide sequence encoding the ADAM6 protein (e.g., ADAM6a or ADAM6b). In some embodiments, the sequence is placed in any suitable location. It may be placed in an intergenic region or any suitable location within the genome. In some embodiments, the nucleic acid encodes a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 98%, 99%, or 100% identical to the sequence of the mouse ADAM6a gene (e.g., 113539230-113547024 of NC_000078.6) or the mouse ADAM6b gene (e.g., 113486188-113492125 of NC_000078.6). In some embodiments, the nucleic acid further comprises regulatory elements (e.g., promoters) of the ADAM6a and ADAM6b genes.

[0336] In some embodiments, the functional mouse ADAM6 locus may be located in the middle of the human IGHV gene cluster. In some embodiments, the mouse ADAM6 locus is located between two human IGHV genes. In some embodiments, the human ADAM6 pseudogene between human VH1-2 and human VH(II)-1-1 is replaced by the mouse ADAM6 locus. In some embodiments, in the animal genome, the ADAM6a and ADAM6b genes are located between human IGHV1-2 and human VH(II)-1-1. In some embodiments, the mouse ADAM6 sequence may be located near the location of the human ADAM6 pseudogene or near the location of the mouse ADAM6 sequence (e.g., within the VD gene region). In some embodiments, the genetically modified mouse has a humanized heavy chain immunoglobulin locus. In some embodiments, mouse ADAM6a and mouse ADAM6b are located between the human IGHV1-2 and IGHV6-1 genes. Placing mouse ADAM6a and mouse ADAM6b between the human IGHV1-2 and IGHV6-1 genes may have several advantages. For example, because these genes replace the human ADAM6 gene at the same locus, the substitution of the human ADAM6 gene has a limited effect on VDJ recombination, and the mouse ADAM6a and mouse ADAM6b genes can also function normally (as in positions similar to endogenous loci).

[0337] Therefore, in one aspect, this disclosure provides genetically modified animals comprising, at the endogenous heavy chain immunoglobulin locus: a first sequence comprising one or more human IGHV genes; a second sequence comprising an ADAM6 gene; and a third sequence comprising one or more human IGHD genes and one or more human IGHJ genes. In some embodiments, the first, second, and third sequences are operatively linked.

[0338] In some embodiments, the first sequence comprises all IGHV genes listed in Table 5 except for IGHV2-10, IGHV3-9, IGHV1-8, IGHV(II)-1-1, and IGHV6-1. In some embodiments, the first sequence comprises all IGHV genes listed in Table 5 except for IGHV5-10-1, IGHV3-64D, IGHV(II)-1-1, and IGHV6-1. In some embodiments, the first sequence comprises IGHV5-10-1 and IGHV3-64D. In some embodiments, the first sequence is an unmodified sequence derived from a human heavy chain immunoglobulin locus.

[0339] In some embodiments, the second sequence comprises one or both of the mouse ADAM6a and mouse ADAM6b genes. In some embodiments, the animal is a fertile male mouse. In some embodiments, the second sequence does not contain the mouse ADAM6a or mouse ADAM6b genes.

[0340] In some embodiments, the third sequence comprises all human IGHD genes in Table 6 and all human IGHJ genes in Table 7. In some embodiments, the third sequence comprises human IGHV6-1. In some embodiments, the third sequence comprises human IGHV(II)-1-1. In some embodiments, the third sequence is an unmodified sequence derived from a human heavy chain immunoglobulin locus.

[0341] In some embodiments, AMAM6a and / or ADAM6b are endogenous sequences. In some embodiments, AMAM6a and / or ADAM6b are not substituted and / or are located at their endogenous or natural positions. In some embodiments, the mouse IGHV gene preceding mouse IGHV1-2 at the heavy chain variable region locus is replaced by a human IGHV gene. In some embodiments, the mouse IGHV, IGHD, and IGHJ genes following mouse IGHV6-1 at the heavy chain variable region locus are replaced by one or more human IGHV, IGHD, and / or IGHJ genes.

[0342] Therefore, in some embodiments, the mouse IGHV, IGHD, and IGHJ genes can be substituted more than once. In the first step, a selected number of mouse IGHV genes on the 5' side of ADAM6a (e.g., all mouse IGHV genes in Table 8) are substituted with human IGHV genes. In the second step, a selected number of mouse IGHD and IGHJ genes on the 3' side of ADAM6b are substituted with human IGHD and human IGHJ genes (e.g., all mouse IGHD genes except IGHD5-1 and IGHD3-1 in Table 9 and all IGHJ genes in Table 10). Substitution can be performed via homologous recombination or Cre-mediated recombination.

[0343] In some embodiments, the mice do not possess the mouse ADAM6a or ADAM6b gene. In some embodiments, the mice possess the human ADAM6 gene.

[0344] Various methods can be used to enhance mouse fertility. In some embodiments, female mice exhibiting superovulation can be used for mating. In some embodiments, in vitro fertilization can be used. Superovulation can be induced by injecting serum gonadotropins and human chorionic gonadotropin (e.g., human or mouse CG) into mature female mice. Mature male mice can be sacrificed, and their epididymal tails can be isolated. The ducts of the epididymal tails are cut to release sperm. Next, superovulating mature female mice can be sacrificed, and the oviducts isolated. The cumulus-oocyte complex (COC) can be released from the oviducts. Next, a sperm suspension can be added to the COC and incubated for fertilization. Pathogenic oocytes containing only one pronucleus can be removed. After incubation, 2-cell stage embryos can be transferred to recipient females. Methods for enhancing mouse fertility are known in the art.

[0345] This disclosure also provides nucleic acid sequences that are at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any nucleotide sequence as described herein. Furthermore, an amino acid sequence is provided that is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any amino acid sequence as described herein.

[0346] In some embodiments, this disclosure relates to a nucleotide sequence encoding any peptide as described herein, or to any amino acid sequence encoded by any nucleotide sequence as described herein. In some embodiments, the nucleic acid sequence is less than 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 150, 200, 250, 300, 350, 400, 500, or 600 nucleotides. In some embodiments, the amino acid sequence is less than 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, or 400 amino acid residues.

[0347] In some embodiments, the amino acid sequence (i) comprises an amino acid sequence; or (ii) consists of an amino acid sequence, wherein the amino acid sequence is any of the sequences described herein.

[0348] In some embodiments, the nucleic acid sequence (i) comprises a nucleic acid sequence; or (ii) consists of a nucleic acid sequence, wherein the nucleic acid sequence is any of the sequences described herein.

[0349] To determine the percentage of identity between two amino acid sequences or two nucleic acid sequences, the sequences are paired for optimal comparison purposes (e.g., gaps are introduced in one or both of the first and second amino acids or the first and second nucleic acid sequences for optimal alignment, and non-homologous sequences can be ignored for comparison purposes). The amino acid residues or nucleotides at corresponding amino acid or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. Taking into account the number of gaps and the length of each gap, the percentage of identity between two sequences is a function of the number of identical positions shared by the sequences, which need to be introduced for optimal alignment of the two sequences. For illustrative purposes, the comparison of two sequences and the determination of the percentage of identity between them can be achieved, for example, using a Blosum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.

[0350] The percentage of conserved residues with similar physicochemical properties (homology percentage), such as leucine and isoleucine, can also be used to measure sequence similarity. Families of amino acid residues with similar physicochemical properties have been defined in the art. These families include, for example, amino acids with the following side chains: basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In many cases, the homology percentage is higher than the identity percentage. Therefore, this disclosure also provides amino acid sequences, or nucleic acids encoding such amino acid sequences, that have at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology with any amino acid sequence as described herein.

[0351] Methods using genetically modified animals

[0352] The genetically modified animals can be used to generate humanized or chimeric antibodies that specifically bind to a target. In some embodiments, standard techniques for preparing polyclonal and monoclonal antibodies can be used to use a target (e.g., a protein or a fragment of a protein) as an immunogen to generate antibodies in these animals. In some embodiments, the genetically modified animals are exposed to the antigen for a period of time under conditions that allow the animals to produce antibodies specific to the selected antigen.

[0353] Polyclonal antibodies can be generated in animals through multiple injections (e.g., subcutaneous or intraperitoneal). In some embodiments, the antigenic peptide or protein is injected together with at least one adjuvant. In some embodiments, the antigenic peptide or protein can be conjugated to an immunogenic agent in the species to be immunized. The antigenic peptide or protein can be injected into the animal more than once (e.g., two, three, or four times).

[0354] Full-length polypeptides or proteins can be used; alternatively, their antigenic peptide fragments can be used as immunogens. The antigenic peptide of a protein comprises at least 8 (e.g., at least 10, 15, 20, or 30) amino acid residues of an amino acid sequence and covers an epitope of the protein, such that the resulting antibody against the peptide forms a specific immune complex with the protein.

[0355] Immunogens are commonly used to generate antibodies by immunizing suitable subjects (e.g., genetically modified animals as described herein). Suitable immunogenic formulations may contain, for example, recombinantly expressed peptides or chemically synthesized peptides (e.g., fragments of proteins). The formulation may further contain adjuvants, such as Freund's complete or incomplete adjuvants or similar immunostimulants.

[0356] As described above, polyclonal antibodies can be prepared by immunizing suitable subjects with a polypeptide or its antigenic peptide (e.g., a portion of a protein) as an immunogen. Changes in antibody titers over time in immunized subjects can be monitored using standard techniques, such as enzyme-linked immunosorbent assay (ELISA) using immobilized polypeptides or peptides. If desired, antibody molecules can be isolated from mammals (e.g., from blood) and further purified using well-known techniques (e.g., protein A or protein G chromatography) to obtain the IgG fraction. At an appropriate time following immunization, such as when the specific antibody titer is highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies using standard techniques, such as hybridoma technology originally described by Kohler et al. (Nature 256:495-497, 1975), human B-cell hybridoma technology (Kozbor et al., Immunol. Today 4:72, 1983), EBV hybridoma technology (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1985), or trioma technology. Techniques for generating hybridomas are well-known (see Current Protocols in Immunology, 1994, Coligan et al. (eds.), John Wiley & Sons, Inc., New York, NY). Monoclonal antibody-producing hybridoma cells are detected by, for example, screening hybridoma culture supernatants for antibodies binding to target peptides or epitopes using standard ELISA assays.

[0357] In one aspect, this disclosure provides a modified mouse comprising an endogenous immunoglobulin heavy chain gene locus, wherein the mouse produces B cells comprising a rearranged immunoglobulin sequence operably linked to a heavy chain constant region gene sequence. In some embodiments, the rearranged immunoglobulin sequence operably linked to the heavy chain constant region gene sequence comprises human heavy chain V, D, and / or J sequences. In some embodiments, the heavy chain constant region gene sequence comprises a human or mouse heavy chain sequence selected from the group consisting of CH1, hinge, CH2, CH3, and combinations thereof.

[0358] In one aspect, this disclosure provides a mouse modified with an endogenous immunoglobulin light chain (e.g., κ or λ) locus, wherein the mouse produces B cells comprising a rearranged immunoglobulin sequence operably linked to a light chain constant region gene sequence. In some embodiments, the rearranged immunoglobulin sequence operably linked to the light chain constant region gene sequence comprises human light chain V and / or J sequences. In some embodiments, the light chain constant region gene sequence comprises a human or mouse light chain constant region.

[0359] The mouse B cells or spleen cells may contain, for example, rearranged non-mouse immunoglobulin variable gene sequences operatively linked to mouse immunoglobulin constant region genes. Sequences encoding human heavy chain variable regions and human light chain variable regions are determined. These sequences can be determined, for example, by sequencing the target hybridoma or B cells. In some embodiments, single B cell screening is used. This allows screening of natural antibody lineages without hybridoma fusion and combined display. For example, B cells can be mixed with a small set of DNA barcode-encoded antigens, allowing the recovery of one or more antigen barcodes and B cell receptor (BCR) sequences from a single B cell using a single-cell sequencing protocol.

[0360] Antibodies can be further modified, for example, by operatively linking a sequence encoding the variable region of the human heavy chain to a sequence encoding the constant region of the human heavy chain, and / or operatively linking a sequence encoding the variable region of the human light chain to a sequence encoding the constant region of the human light chain, to obtain humanized antibodies or human antibodies.

[0361] This disclosure also provides methods for preparing antibodies, nucleic acids, cells, and tissues (e.g., spleen tissue). In some embodiments, the methods include exposing an animal, as described herein, to an antigen. Antibodies (e.g., chimeric antibodies), nucleic acids encoding the antibodies, cells, and / or tissues (e.g., spleen tissue) can be obtained from the animal. In some embodiments, nucleic acids encoding the variable regions of human heavy chain and light chain immunoglobulins can be determined, for example, by sequencing. In some embodiments, nucleic acids encoding the variable regions of human heavy chain immunoglobulins can be operatively linked to nucleic acids encoding the constant regions of human heavy chain immunoglobulins. In some embodiments, nucleic acids encoding the variable regions of human light chain immunoglobulins can be operatively linked to nucleic acids encoding the constant regions of human light chain immunoglobulins. In some embodiments, cells containing nucleic acids as described herein are cultured and antibodies are collected.

[0362] In some embodiments, mouse immunoglobulin V, D, and J genes (e.g., mouse IGHV, IGHD, IGHJ, IGKV, or IGKJ genes) do not contribute to the heavy chain and / or light chain variable region sequences. In some embodiments, the heavy chain and / or light chain variable region sequences generated by the animal are entirely human and are entirely contributed by human immunoglobulin V, D, and J genes (e.g., human IGHV, IGHD, IGHJ, IGKV, and IGKJ genes).

[0363] Variants of the antibodies or antigen-binding fragments described herein can be prepared by introducing appropriate nucleotide changes into the DNA encoding the human antibodies, humanized antibodies, or chimeric antibodies or their antigen-binding fragments, or by peptide synthesis. Such variants include, for example, deletions, insertions, or substitutions of residues within the amino acid sequence constituting the antigen-binding site or antigen-binding domain of the antibody. Within this population of variants, some antibodies or antigen-binding fragments will have increased affinity for the target protein. Any combination of deletions, insertions, and / or combinations can be made to obtain antibodies or their antigen-binding fragments with increased binding affinity to the target. Amino acid changes introduced into the antibody or antigen-binding fragment can also alter or introduce new post-translational modifications into the antibody or antigen-binding fragment, such as altering (e.g., increasing or decreasing) the number of glycosylation sites, altering the type of glycosylation sites (e.g., altering the amino acid sequence so that enzymes present in the cell link different sugars), or introducing new glycosylation sites.

[0364] The antibodies disclosed herein can be derived from any animal species, including mammals. Non-limiting examples of natural antibodies include antibodies derived from: humans, primates (e.g., monkeys and apes), cattle, pigs, horses, sheep, camels (e.g., camels and llamas), chickens, goats, and rodents (e.g., rats, mice, hamsters, and rabbits), including genetically engineered transgenic rodents to produce human antibodies.

[0365] Human and humanized antibodies include antibodies having variable and constant regions derived from human immunoglobulin sequences (or having the same amino acid sequence as that derived from human immunoglobulin sequences). Human antibodies may include amino acid residues not encoded by human immunoglobulin sequences (e.g., mutations introduced by in vitro random mutagenesis or site-specific mutagenesis or by in vivo somatic mutations), such as in CDR.

[0366] Further modifications can be made to the antibody or antigen-binding fragment. For example, one or more cysteine ​​residues can be introduced into the Fc region, thereby allowing interchain disulfide bonds to form in this region. The resulting homodimeric antibody can have any increased in vitro and / or in vivo half-life. Homodimeric antibodies with increased in vitro and / or in vivo half-life can also be prepared using heterobifunctional crosslinkers as described, for example, by Wolff et al. (Cancer Res. 53:2560-2565, 1993). Alternatively, antibodies having two Fc regions can be engineered (see, for example, Stevenson et al., Anti-Cancer Drug Design 3:219-230, 1989).

[0367] In some embodiments, antibodies or their antigen-binding fragments may be covalently modified. These covalent modifications can be performed by chemical or enzymatic synthesis, or by enzymatic cleavage or chemical cutting. Other types of covalent modifications to antibodies or antibody fragments are introduced into the molecule by reacting the target amino acid residues of the antibody or fragment with an organic derivatizer capable of reacting with selected side chain or N-terminal or C-terminal residues.

[0368] Method for preparing bispecific antibodies using shared light chains

[0369] This disclosure provides genetically engineered animals that express a limited lineage of light chains that can be associated with a variety of heavy chains. In various embodiments, an endogenous κ light chain variable region gene is deleted and replaced with one, two, three, four, or five human light chain variable region genes, operatively linked to an endogenous κ constant region gene. In various embodiments, the animal also includes a nonfunctional λ light chain locus, or a deletion thereof that prevents the locus from producing λ light chains.

[0370] In some embodiments, the animal includes a light chain variable region locus lacking an endogenous light chain variable gene and containing a rearranged human V / J sequence operatively linked to an endogenous constant region, and wherein the locus expresses a light chain comprising a human V / J sequence linked to an endogenous constant region.

[0371] In various embodiments, when immunized with a target antigen, genetically engineered animals produce B cells exhibiting multiple rearrangements of the variable region of the human immunoglobulin heavy chain. These rearrangements are expressed and processed using a limited number (e.g., 1, 2, 3, 4, 5) of rearranged light chains, including embodiments where one or two light chains contain the variable region of the human light chain, which contains, for example, 1 to 5 somatic mutations. In some embodiments, at least 50%, 60%, 70%, 80%, 90%, or 95% of the variable region of the human light chain has at least one somatic mutation. In some embodiments, at least 50%, 60%, 70%, 80%, 90%, or 95% of the variable region of the human light chain has at least two somatic mutations. In some embodiments, at least 50%, 60%, 70%, 80%, 90%, or 95% of the variable region of the human light chain has at least three somatic mutations.

[0372] In some embodiments, the somatic hypermutation rate is relatively low. In some embodiments, no more than 30% or 40% of the human light chain variable regions have one or more somatic mutations. In some embodiments, no more than 20% of the human light chain variable regions have two or more somatic mutations.

[0373] In some embodiments, as described herein, the animal can be immunized with a first immunogen to generate B cells, said B cells expressing antibodies that specifically bind to a first epitope. The animal can also be immunized with a second immunogen to generate B cells, said B cells expressing antibodies that specifically bind to a second epitope. The heavy chain variable region can be cloned from B cells onto a vector for transfecting cells to express a rearranged human heavy chain variable region fused to the human heavy chain constant region, and a common light chain variable region fused to the human light chain constant region.

[0374] In some embodiments, the methods described herein are designed for the preparation of bispecific antibodies. Bispecific antibodies can be prepared by engineering the interface between a pair of antibody molecules to maximize the percentage of heterodimers recovered from recombinant cell cultures. For example, the interface may contain at least a portion of the CH3 domain of the antibody's constant structural domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). By replacing the large amino acid side chains with smaller amino acid side chains (e.g., alanine or threonine), a compensating "cavity" of the same or similar size as the one or more large side chains is created at the interface of the second antibody molecule. This provides a mechanism for increasing the yield of heterodimers relative to other unwanted end products as dimers. This method is described, for example, in WO96 / 27011, which is incorporated herein by reference in its entirety.

[0375] In some embodiments, a knob-to-hole (KIH) technique may be used, which involves engineering the CH3 domain to create a "knob" or "hole" on each heavy chain to facilitate heterodimerization. The KIH technique is described, for example, in "Production of bispecific antibodies in 'knobs-into-holes' using a cell-free expression system" by Xu, Yiren, et al., MAbs., Vol. 7, No. 1, Taylor and Francis, 2015, which is incorporated herein by reference in its entirety. In some embodiments, one heavy chain has a T366W and / or S354C (knob) substitution (EU number), and the other heavy chain has a Y349C, T366S, L368A, and / or Y407V (hole) substitution (EU number). In some embodiments, one heavy chain has one or more of the following substitutions: Y349C and T366W (EU number). The other heavy chain may have one or more of the following substitutions: E356C, T366S, L368A, and Y407V (EU designation). In some embodiments, one heavy chain has a T366Y (mortar) substitution, and the other heavy chain has one, two, or three of these substitutions: T366S, L368A, and Y407V (mortar).

[0376] In addition, anion exchange chromatography can be used to purify bispecific antibodies. Anion exchange chromatography is a method for separating substances based on using an ion exchange resin containing positively charged groups such as diethyl-aminoethyl (DEAE) as a charge. In solution, the resin is coated with positively charged counterions (cations). An anion exchange resin will bind to negatively charged molecules, displacing the counterions. Anion exchange chromatography can be used to purify proteins based on their isoelectric point (pI). The isoelectric point is defined as the point at which a protein carries no net charge. When pH>pI, the protein has a net negative charge, and when pH<pI, the protein has a net positive charge. Therefore, in some embodiments, different amino acid substitutions can be introduced into the two heavy chains, so that the pI of the homodimer comprising two Arm A and the pI of the homodimer comprising two Arm B are different. As used herein, the term "arm" of a bispecific antibody refers to the antigen-binding site in the bispecific antibody that specifically binds a particular antigen (or epitope). The pI of a bispecific antibody having Arm A and Arm B will be between the two pIs of the homodimers. Therefore, the two homodimers and the bispecific antibody can be eluted under different pH conditions. The present disclosure shows that some amino acid residue substituents can be introduced on the heavy chain to modulate the pI. Therefore, in some embodiments, the amino acid residue at position 83 (Kabat numbering) in VH is lysine, arginine or histidine. In some embodiments, the amino acid residue at one or more positions of 1, 6, 43, 81 and 105 (Kabat numbering) in VH is aspartic acid or glutamic acid. In some embodiments, the amino acid residue at one or more positions of 13 and 105 (Kabat numbering) is aspartic acid or glutamic acid. In some embodiments, the amino acid residue at one or more positions of 13 and 42 (Kabat numbering) is lysine, arginine, histidine or glycine.

[0377] Examples

[0378] Example 1: Overview

[0379] Experiments were conducted to introduce human immunoglobulin genes into the mouse genome to generate mice expressing humanized antibodies. Figure 1A A method for generating humanized mice is illustrated. The method first involves modifying the human immunoglobulin region on a human chromosome. The modified human chromosome is then introduced into a mouse recipient cell.

[0380] The mouse immunoglobulin variable regions are replaced with human immunoglobulin variable regions by direct replacement (e.g., homologous recombination or Cre-mediated recombination). In some cases, the human immunoglobulin variable regions can be introduced into the mouse genome by a stepwise approach. Then, recipient cells with correct replacement are screened. The cells are then injected into blastocysts to generate chimeric mice. Subsequent breeding is performed to obtain mice containing human or humanized immunoglobulin variable regions.

[0381] Because the mouse heavy chain gene and the two light chain genes are located on chromosomes 12, 6, and 16, respectively, mice containing either the human heavy chain variable region or the human light chain variable region can be generated. These mice can then be crossbred to obtain mice that express both the human heavy chain variable domain and the human common light chain variable domain.

[0382] Example 2: Modification of mouse heavy chain immunoglobulin gene loci

[0383] The heavy chain immunoglobulin locus is located on mouse chromosome 12. Two recombination sites were introduced on either side of the variable region of the heavy chain immunoglobulin locus.

[0384] Experiments were also conducted to generate modified human chromosomes. Two recombination sites were introduced flanking the variable region of the heavy chain immunoglobulin locus. The modified human chromosomes were then introduced into mouse cells. Cells were then screened, selecting only cells containing a single human chromosome. Cre recombinase then mediated the substitution of the V, D, and J regions of the mouse chromosome with the V, D, and J regions of the human chromosome. Figure 1B ).

[0385] Positive clonal cells were injected into the blastocysts of BALB / c mice via microinjection. Embryo microinjection was performed according to methods described, for example, A. Nagy et al., “Manipulating the Mouse Embryo: A Laboratory Manual (3rd Edition),” Cold Spring Harbor Laboratory Press, 2003. The injected fertilized eggs were then transferred to a culture medium for a short period before being transplanted into the oviducts of recipient mice to produce genetically modified humanized mice (F0 generation). These mice were then mated with mice with a C57BL / 6 background. DNA obtained from the mouse tail was analyzed by PCR. The mice were further crossbred several times (e.g., at least 5 times) with mice having a BALB / c background to obtain heterozygous mice with a humanized heavy chain immunoglobulin locus having a BALB / c background.

[0386] Heterozygous mice were then mated to obtain homozygous mice. A detailed description of how to prepare homozygous mice from the humanized heavy chain immunoglobulin locus can be found in PCT / CN 2020 / 075698, submitted on February 18, 2020, which is incorporated herein by reference in its entirety.

[0387] Example 3: Sequence design of the VJ region in a light chain

[0388] The application of human light chain variable region sequences in various antibodies was analyzed.

[0389] (1) Data were collected from the IMGT / GeneFrequency database. Statistical analysis showed that the five most utilized κ light chain V region genes were: IGKV3-20, IGKV1-39 / IGKV1D-39, IGKV3-11, IGKV3-15, and IGKV4-1. The three most utilized κ light chain J region genes were: IGKJ1, IGKJ2, and IGKJ4.

[0390] Table 12

[0391]

[0392]

[0393]

[0394] 2) Analysis of light chain genetic information of 110 antibody molecules. Sequence information was collected from the IMGT / mAb-DB database. Statistical analysis showed that the five most abundant κ light chain V region genes were IGKV3-20, IGKV3-11, IGKV3-15, IGKV1-39 / IGKV1D-39, and IGKV1-12 / IGKV1D-12; and the three most utilized κ light chain J region genes were IGKJ1, IGKJ4, and IGKJ2. Figure 2A-2B ).

[0395] Based on the analysis, three human light chain V regions (IGKV3-20, IGKV3-11 and IGKV1-39) and two human light chain J regions (IGKJ1 and IGKJ4) were selected as humanized light chain immunoglobulin loci.

[0396] Example 4: Preparation of rearranged light chain mice

[0397] The mouse light chain immunoglobulin gene locus is located on mouse chromosome 6. Figure 3A This is a schematic diagram illustrating the mouse light chain immunoglobulin gene locus. The entire mouse VJ region in wild-type mice can be replaced by a rearranged human light chain VJ region sequence. Figure 3B Alternatively, the process can be performed in steps, i.e., the mouse VJ region can be knocked out first (e.g., replaced with a sequence containing Neo and DTR), and then a sequence containing the rearranged human light chain VJ region can be inserted.

[0398] For example, mouse chromosome 6 was modified by knocking out the entire variable region of the κ light chain immunoglobulin locus. Three different rearranged human light chain VJ sequences were constructed and then inserted into the κ chain VJ region of mouse chromosome 6.

[0399] A diagram illustrating the humanization strategy is shown below. Figure 4As shown, three homologous recombination targeting vectors with common sequence characteristics were constructed; that is, each homologous recombination targeting vector has upstream and downstream homologous arm sequences and a rearranged human light chain VJ sequence. For each vector, the rearranged human VJ sequence was selected selectively. The three vectors contain rearranged human IGKV1-39 / J4, IGKV3-11 / J1, and IGKV3-20 / J1 sequences, respectively. IGKV1-39 (SEQ ID NO:1) is identical to the nucleotide sequences 89319625-89320099 of NCBI accession number NC_000002.12; IGKV3-11 (SEQ ID NO:2) is identical to the nucleotide sequences 89027171-89027684 of NCBI accession number NC_000002.12; IGKV3-20 (SEQ ID NO:3) is identical to the nucleotide sequences 89142574-89143108 of NCBI accession number NC_000002.12; and IgKJ1 (SEQ ID NO:1) is identical to the nucleotide sequences 89319625-89320099 of NCBI accession number NC_000002.12. NO:4) is identical to the nucleotide sequence 88861886-88861923 of NCBI accession number NC_000002.12; IgKJ4 (SEQ ID NO:5) is identical to the nucleotide sequence 88860886-88860923 of NCBI accession number NC_000002.12.

[0400] In addition, each rearranged human light chain VJ sequence also contains the human V promoter sequence of the light chain V region gene. The promoter sequence is approximately 2000 bp prior to the V region gene.

[0401] In addition, there may be a separate auxiliary sequence after each rearranged human VJ sequence, for example, a mouse 3'UTR sequence (SEQ ID NO:6) or a human 3'UTR sequence (SEQ ID NO:7) following the human light chain VJ region.

[0402] Three vectors were introduced into cells via gene editing, and cells were selected using DT selection. Positive clones were identified by PCR and Southern blotting. PCR assays were performed using the following primers:

[0403] Table 13

[0404]

[0405]

[0406] In Table 13, L-GT-F is located on the 5' homologous arm; R-GT-R is located on the 3' homologous arm; L-GT-R and R-GT-F are located on the rearranged human light chain VJ sequence; and the primers m-5'loxp-L-GT-F, m-5'loxp-R-GT-R, m-3'lox-L-GT-F, and m-3'lox-R-GT-R are located on the humanized heavy chain chromosome.

[0407] Southern blot analysis was performed using the following probes:

[0408] Table 14

[0409]

[0410]

[0411] In Table 14, the 5' probe is located outside the 5' homologous arm; the 3' probe is located outside the 3' homologous arm; and the IGKV1-39, IGKV3-11, and IGKV3-20 probes are located on the humanized fragment.

[0412] Positive clonal cells were injected into the blastocysts of BALB / c mice via microinjection. Embryo microinjection was performed according to methods described, for example, in A. Nagy et al., “Manipulating the Mouse Embryo: A Laboratory Manual (3rd Edition),” Cold Spring Harbor Laboratory Press, 2003. The injected fertilized eggs were then transferred to a culture medium for a short period before being transplanted into the oviducts of recipient mice to produce genetically modified humanized mice (F0 generation). Chimeric mice were mated with homozygous humanized mice of the heavy chain gene to produce F1 generation mice. DNA obtained from the tails of F1 generation mice was subjected to PCR and Southern blotting analysis to determine whether positive heterozygous mice were obtained.

[0413] Example 5: Common Light Chain Expression

[0414] mRNA sequences of the light chain variable region in mice were analyzed by sequencing. Unimmunized (unexposed to specific antigens) humanized mice (hybridized humanized heavy chains and hybrid rearranged light chains) were selected, and RNA was extracted from orbital blood samples. Reverse transcription was performed using a 5'RACE kit (SMARTer RACE 5' / 3' kit, Takara Bio USA, Inc., catalog number 634858) to obtain cDNA. The obtained cDNA was amplified using the IGKC-R primers and UPM primers from the 5'RACE kit. The heavy chain variable region sequence fragment was then sequenced. The IGKC-R primer sequence was 5'-CTAACACTCATTCCTGTTGAAGCTCTTGAC-3' (SEQ ID NO:34). Sequencing results were compared with the NCBI Ig Blast tool to identify human immunoglobulin sequences, specifically identifying the use of human Vκ and Jκ region genes. The results showed that 89% of 577 clones from three mouse species (randomly selected) expressed human Vκ and Jκ, with the proportion of human Vκ and Jκ exceeding 60% in each mouse. This indicates that human Vκ and Jκ genes are efficiently and dominantly expressed in humanized mice after the endogenous K-chain variable region locus is completely replaced by rearranged sequences of the human immunoglobulin light chain. Conversely, in heterozygous mice, the wild-type κ chain is not expressed or expressed at low levels.

[0415] Table 15

[0416]

[0417]

[0418] Example 6: B cell development in hVH / hcVL mice

[0419] F1 generation mice were crossbred. Homozygous humanized heavy chain immunoglobulin locus and heterozygous humanized common light chain immunoglobulin locus (humanized VH) were used. H / H / cVL K / + Mouse, abbreviated as hVH H / H / hcVL K / + Mice were used to detect B cell development. Mice possessing both a humanized VH locus (heterozygous or homozygous) and a shared light chain immunoglobulin locus (heterozygous or homozygous) are also called hVH / hcVL mice. Experiments were conducted to compare pre-immune hVH levels. H / H / hcVL K / + Immune system of mice and wild-type mice. Body weight and the weight of some organs, such as spleen, thymus, liver, heart, lungs and kidneys, were measured in wild-type and hVH / hcVL heterozygous mice (Figs. 5A-5G). There were no significant differences in mean body weight and organ (spleen, thymus, liver, heart, lungs and kidneys) weight between wild-type and hVH / hcVL heterozygous mice.

[0420] Flow cytometry was used to analyze the blood of wild-type and hVH / hcVL heterozygous mice. Figure 6A ),spleen( Figure 6B ) and lymph nodes ( Figure 7 The number and distribution of lymphocytes in the hVH / hcVL heterozygous mice were analyzed. Results showed that the percentages of B cells, T cells, NK cells, CD4+ T cells, and CD8+ T cells in the blood, spleen, and lymph nodes were almost identical to those in wild-type mice. The leukocytes included: B cells (e.g., characterized by CD45+, CD19+, TCR-), T cells, and natural killer (NK) cells (e.g., characterized by CD45+, TCR-, and NK1.1+). Further characteristics of T cells were CD45+, CD19-, and TCR+. CD4+ T cells (CD4) were characterized by CD45+, CD19-, TCR+, CD4+, and CD8-. And CD8+ T cells (CD8) were characterized by CD45+, CD19-, TCR+, CD4-, and CD8+. Flow cytometry analysis contained only intact, single, viable leukocytes.

[0421] Figure 8A The percentage of B cells at different developmental stages in the bone marrow was shown. B cell progenitor cells in the bone marrow were analyzed by flow cytometry. Based on the expression levels of B220 and CD43, B cell progenitor cells in the bone marrow could be divided into three cell populations: pre-B cells (characterized by B220 expression)... 低 CD43 高 IgM 低 ), pre-B cells (characterized by B220) 低 CD43 中 IgM 低 ) and immature B cells (characterized by B220) 高 CD43 低 IgM 高 No significant differences were observed between wild-type mice and hVH / hcVL mice. Furthermore, B cell development in the bone marrow was assessed by flow cytometry to evaluate plasma cell (B220) development. 低 IgM - IgD - CD138 + ) and memory B cells (B220) + IgM + IgD - CD38 + Selective coloring () Figure 8B No significant differences were observed between wild-type mice and hVH / hcVL mice.

[0422] Figure 9The percentage of B cells at different developmental stages is shown. The developmental stages of B cells in the spleen are divided into T1 (transitional type 1 B cells, characterized by B220). + IgM + IgD - T2 (transitional type 2 B cell, characterized by B220) + IgM + IgD + ) and mature B cells (characterized by B220) + IgM 低 IgD + No significant differences were observed between wild-type mice and hVH / hcVL mice.

[0423] B cell development in the spleen was also assessed by flow cytometry to evaluate plasma cell (B220) development. 低 IgM - IgD - CD138 + ) and memory B cells (B220) + IgM + IgD - CD38 + Selective coloring () Figures 10A-10B No significant differences were observed between wild-type mice and hVH / hcVL mice. Additionally, significant differences were also observed in the spleen marginal zone (marginal zone B cells, MZ-B, characterized by B220). + CD21 + CD23 - ) and follicular regions (follicular B cells, called FO-B, characterized by B220) + CD21 低 CD23 + The development of B cells was assessed. Figure 10C The percentage of splenic B cells is shown in the marginal zone (MZ-B) and follicular zone (FO-B). No significant differences were observed between wild-type mice and hVH / hcVL mice.

[0424] Light chain utilization of B cells in the spleen was assessed using flow cytometry. First, mB220 (Pacific Blue) was used. TMB cells were selectively labeled with anti-mouse / human CD45R / B220 Antibody (BioLegend, Cat#103227), and then labeled with mIgGκ-FITC (FITC anti-mouse Ig light chain κ Antibody, BioLegend, Cat#409509) and mIgG lambda-PE (PE anti-mouse Ig light chain λ Antibody, BioLegend, Cat#407307). No significant differences were observed between wild-type mice and hVH / hcVL mice. The results indicate that humanization does not affect the expression levels of κ and λ chains in the spleen of hVH / hcVL heterozygous mice (Figures 11A-11I).

[0425] Figure 12A The percentage of B cells at different developmental stages is shown. The developmental stages of B cells in lymph nodes are divided into T1 (transitional type 1 B cells, characterized by B220). + IgM + IgD - T2 (transitional type 2 B cell, characterized by B220) + IgM + IgD + ) and mature B cells (characterized by B220) + IgM 低 IgD + No significant differences were observed between wild-type mice and hVH / hcVL mice. B cell development in lymph nodes was also assessed by flow cytometry to evaluate plasma cells (B220). 低 IgM - IgD - CD138 + ) and memory B cells (B220) + IgM + IgD - CD38 + Selective coloring () Figure 12B No significant differences were observed between wild-type mice and hVH / hcVL mice.

[0426] Light chain utilization of lymph node B cells was assessed by flow cytometry. B cells were first selectively labeled with mB220, and then labeled with mIgGκ-FITC and mIgGλ-PE. No significant differences were observed between wild-type mice and hVH / hcVL mice. The results indicate that humanization does not affect the expression levels of κ and λ chains in the spleen of hVH / hcVL heterozygous mice (Figures 13A-13I).

[0427] Perform experiments to evaluate hVH H / H / hcVL K / K B cell development in mice. Wild-type and hVHH / H / hcVL K / K There were no significant differences among mice in B cell development and average weight of immune organs (e.g., spleen). Figure 13J As shown, hVH was quantitatively measured using ELISA before antigen immunization. H / H / hcVL K / K Different immunoglobulin (Ig) subtypes were observed in the serum of mice compared to wild-type mice. No significant differences were observed.

[0428] In another similar experiment, hVH was analyzed. H / H / hcVL K / K Ig subtypes in mice and wild-type mice before and after immunization. No significant differences were found. Figure 13H ).

[0429] Example 7: Antibody production in hVH / hcVL mice

[0430] Experiments were performed to evaluate whether B cells in hVH / hcVL mice developed normally. Antigen-specific antibody titers were measured in the serum of immunized hVH / hcVL mice and wild-type mice.

[0431] Immunization of hVH with two different antigens H / H / hcVL K / + Mice and wild-type (C57BL / 6) mice were immunized three times. During the first immunization, mice were injected with complete Freund's adjuvant (CFA) and 20 μg of antigen. Two weeks later, mice were injected with incomplete Freund's adjuvant (IFA) and 20 μg of antigen. Two weeks later, mice were injected with 20 μg of antigen and IFA. Approximately one week after the third immunization, blood samples were collected, and antigen-specific antibody titers in wild-type and hVH / hcVL mice were analyzed using ELISA. H / H / hcVL K / + The mice primarily expressed antibodies with humanized shared light chain variable regions.

[0432] ELISA was performed as follows. The his-labeled antigen was diluted to 0.5 μg / ml in 1×PBS, and 0.1 ml was added to each well of a 96-well plate. The plate was then incubated at 37°C for 2 hours. After incubation, each well was washed three times with 300 μl of 1×PBST, and then blocked at 37°C for 1 hour with 250 μl of 1×PBS and 5% skim milk. Each well was then washed twice with 300 μl of 1×PBST. Serum samples from hVH / hcVL mice or wild-type mice were diluted with 1×PBS at dilutions of 1:500, 1:2000, 1:8000, 1:32000, 1:128000, 1:512000, or 1:2048000, and then added to the 96-well plate. Serum samples from unimmunized mice were also diluted 1:500 and added to the plate as a blank control. Diluted serum samples (120 μl / well) were incubated in 96-well plates at 37°C for 1 hour. After incubation, the plates were washed five times with 300 μl / well of 1×PBST. Then, the plates were incubated for 1 hour at 37°C with 0.1 ml / well of 1:20000 diluted goat anti-mouse IgGFc (HRP). After incubation, the plates were washed five times with 300 μl / well of 1×PBST. Next, 0.1 ml of TMB developing solution was added to each well, and the plates were incubated in the dark at room temperature for 10 minutes, followed by the addition of 0.1 ml of stop solution to each well. OD450 and OD570 were measured using a plate reader. Figure 24-25 The standard OD value is calculated as follows: Standard OD value = OD450 - OD570.

[0433] The antigen-specific antibody titers after the third immunization were as follows: Figure 24 and Figure 25 As shown in the figure. The results indicate that hVH / hcVL mice can produce antibodies that specifically bind to the antigen, and the immune response is similar between wild-type and hVH / hcVL mice. In particular, the serum antibody titers are similar to those of wild-type mice.

[0434] Example 8: Antibody production in hVH / hcVL mice

[0435] hVH was immunized with TFR1 and Ova respectively. H / H / hcVL K / K Mice and wild-type mice (3 mice per group). Then use... A photofluidic system was used to separate plasma cells capable of producing antigen-specific monoclonal antibodies. The number of positive cells is shown below.

[0436] Table 16

[0437] mice antigen Number of positive cells WT mice TFR1 197 <![CDATA[hVH H / H / hcVL K / K Mice TFR1 220 WT mice Ova 356 <![CDATA[hVH H / H / hcVL K / K Mice Ova 448

[0438] Antigen A is a member of the tumor necrosis factor receptor superfamily. Antigen A is used for hVH. H / H / hcVL K / K Mouse immunization. Forty-two human common light chain antibodies (IGKV3-11 / J1) were obtained. The VH and VL values ​​of these antibodies were added to the constant region of human IgG1 to obtain human antibodies. The affinity of the 42 human common light chain antibodies (IGKV3-11 / J1) against antigen A was then determined using Biacore.

[0439] The purified anti-antigen A antibody was diluted to 1 μg / ml and then injected into the Biacore 8K biosensor at 10 μL / min for approximately 50 seconds to achieve the desired protein density (e.g., approximately 50 response units (RU)). His-labeled antigen A at a concentration of 200 nM was then injected at 30 μL / min for 120 seconds. Dissociation was monitored for 600 seconds. The chip was regenerated after the last injection of each glycine titration (pH 2.0, 30 μL / min, 30 seconds).

[0440] By using Biacore 8K evaluation software 3.0, the data were fitted to a 1:1 Langmuir binding model (Karlsson, R. Roos, H. Fagerstam, L. Petersson, B., 1994. Methods Enzymology 6.99-110), thereby simultaneously obtaining the association rate (kon) and dissociation rate (koff). The affinity (KD = koff / kon) was derived from the quotient of the kinetic rate constant.

[0441] As those skilled in the art will understand, the same method was used for each antibody in each test, with parameters (e.g., antibody concentration) adjusted appropriately. Results showed that, except for A-1C5-IgG1, A-1D10-IgG1, and A-1E1-IgG1, the binding affinity of these antibodies reached or exceeded 10. -8 M indicates that the method can successfully generate antibodies with high binding affinity to antigens.

[0442] Table 17

[0443]

[0444]

[0445] Epitope correlation analysis

[0446] The relative positions of epitopes were analyzed using surface plasmon resonance (SPR) competition assays. A total of 15 monoclonal antibodies were used to investigate their inhibitory (blocking) binding effects on each other: A-1B10-IgG1, A-1D7-IgG1, A-1C8-IgG1, A-1F2-IgG1, A-H6L6-IgG1, A-1F9-IgG1, A-1B1-IgG1, A-1D12-IgG1, A-1E7-IgG1, A-1A7-IgG1, A-1B8-IgG1, A-H7L7-IgG1, A-1E12-IgG1, A-H3L3-IgG1, and A-H8L8-IgG1. Another antibody against antigen A was also used as a PC (positive control).

[0447] HBS-EP+ buffer (10 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES), 150 mM NaCl, 3 mM ethylenediaminetetraacetic acid (EDTA), and 0.05% P20, pH 7.4) was diluted with HBS-EP+ buffer (10×) throughout the experiment and used as the run buffer. Anti-His antibody was immobilized on the surface of the S-series sensor chip CM5 via amino-coupling to generate an anti-His chip (i.e., CM5-Anti-His-Channel 1,8-Chip). Then, 1 M ethanolamine (pH 8.5) was injected to block the remaining active carboxyl groups on the chip surface, followed by equilibration with HBS-EP+ buffer for 2 hours. Recombinant antigen A protein with a His tag (1 μg / ml) was injected into the Biacore 8K biosensor at 10 μL / min for 50 seconds and captured on the anti-His chip to achieve the desired protein density (i.e., 200 RU). A pair of antibodies (200 nM each) were serially injected into the chip at a rate of 30 μL / min. The binding time for the first injected antibody (analyte 1) was 250 seconds, followed by a binding time of 250 seconds for the second antibody (analyte 2). After antibody injection in each analytical cycle, the chip was regenerated twice with glycine buffer (pH 1.7; 30 μL / min, 30 seconds). The same experimental procedure was performed for each pair of monoclonal antibodies to obtain binding inhibition data when each monoclonal antibody was paired with another antibody.

[0448] Binding values ​​for each antibody were obtained using Biacore Insight assessment software. To quantify the interference of one antibody binding to another, binding rates were calculated to compare each antibody pair. The binding rate was defined as the binding value of the second antibody (analyte 2) divided by the binding value of the first antibody (analyte 1). Statistical software was also used for cluster analysis. Epitope correlations were analyzed, and the 15 human anti-antigen A antibodies were classified into 4 epitope clusters (…). Figure 31In summary, A-1B10-IgG1, A-1D7-IgG1, A-1C8-IgG1, and A-1F2-IgG1 have identical or overlapping epitopes; A-1B1-IgG1 and A-1D12-IgG1 have identical or overlapping epitopes; A-1B8-IgG1, A-H7L7-IgG1, and A-1E12-IgG1 have identical or overlapping epitopes; and A-H3L3-IgG1 and A-H8L8-IgG1 have identical or overlapping epitopes. The results indicate that hVH H / H / hcVL K / K Mice can produce antibodies that target multiple epitopes.

[0449] Thermal stability measurement

[0450] Using QuantStudio TM 5. Real-time PCR system, using Protein Thermal Shift TM The staining kit was used to measure the thermostability of 17 human anti-antigen A antibodies.

[0451] The experiment was conducted according to the manufacturer's specifications. The reaction was carried out in two consecutive steps. Specifically, the first step was carried out at 25°C at a rate of 1.6°C per second for 2 minutes, and the second step was carried out at 99°C at a rate of 0.05°C per second for 2 minutes. The melting temperatures (Tm) of each anti-antigen A antibody were determined, as shown in the table below.

[0452] Table 18

[0453] protein Tm (°C) A-1A7-IgG1 69.6 A-1B10-IgG1 71.2 A-1B1-IgG1 68.9 A-1B8-IgG1 74.2 A-1C8-IgG1 73.6 A-1D12-IgG1 70.0 A-1D7-IgG1 72.8 A-1E12-IgG1 76.6 A-1E7-IgG1 73.5 A-1F2-IgG1 73.1 A-1F9-IgG1 72.3 A-H3L3-IgG1 73.9 A-H6L6-IgG1 68.7 A-H7L7-IgG1 76.7 A-H8L8-IgG1 76.7 A-1E1-IgG1 75.8 A-1E4-IgG1 70.8

[0454] The results showed that the Tm values ​​of human anti-antigen A antibodies were above 70℃ or around 70℃, and these antibodies were thermally stable.

[0455] Example 9: Antibody production in hVH / hcVL mice

[0456] Antigen B is a type II transmembrane serine protease. Antigen B is used for hVH H / H / hcVL K / K Mice were immunized with IGKV3-11 / J1. The affinity of eight human common light chain antibodies (IGKV3-11 / J1) against antigen B was then detected using Biacore.

[0457] Table 19

[0458] Antibody Ka(1 / Ms) kd(1 / s) KD(M) B-3E10-hIgG1 1.2E+05 9.8E-06 8.1E-11 B-3E4-hIgG1 2.0E+05 6.2E-05 3.1E-10 B-1H9-hIgG1 1.8E+05 1.2E-04 6.9E-10 B-1G2-hIgG1 2.9E+05 3.1E-04 1.1E-09 B-1A1-hIgG1 1.9E+05 2.8E-04 1.5E-09 B-1E10-hIgG1 1.5E+05 2.7E-04 1.8E-09 B-2D12-hIgG1 3.5E+04 5.3E-08 1.5E-12 B-3D1-hIgG1 3.1E+04 3.4E-07 1.1E-11

[0459] Example 10. Blocking the binding of antigen C ligand to antigen C.

[0460] Human antigen C is an inhibitory receptor on antigen-activated T cells, playing a crucial role in inducing and maintaining self-tolerance. A blocking assay was performed to determine whether 129 anti-human antigen C antibodies could block the binding between human antigen C and its ligand. These antibodies were developed by hVH... H / H / hcVL K / K Produced in mice.

[0461] Anti-antigen C antibody was collected from the CHO-S supernatant. 30 μl of CHO cells (approximately 1 × 10⁻⁶ cells) transiently transfected with human antigen C ligand were then... 5 Add the antibody to each well in the plate. Collect the antibody (approximately 20-200 μg / mL) from the supernatant and then dilute it 10-fold and 100-fold. At 4°C, add 30 μl of titrated antibody and 30 μl of Bitoin-labeled human antigen C (final concentration 1 μg / mL per well) to each well. Incubate the cells with Bitoin-labeled human antigen C and antibody at 4°C for 30 minutes.

[0462] After washing twice with phosphate-buffered saline (PBS), add 50 μl of Alexa to each well. Streptavidin labeled with AF647 (Jackson Immuno Research, Cat#016-600-084) was diluted 1:1000 and incubated at 4°C for 15 minutes, followed by washing with PBS. The AF647 signal was determined by flow cytometry (Thermo Attune NX). The percentage of cells tested containing the streptavidin signal in the flow cytometry analysis is summarized in the table below. The blocking rate decreased with decreasing antibody concentration, indicating that these antibodies can block the binding between antigen C and its ligand.

[0463] Table 20

[0464]

[0465]

[0466]

[0467]

[0468] Twenty-three antibodies were selected, and their cross-reactivity with mouse antigen C, monkey antigen C, and canine antigen C was determined by flow cytometry. The results are shown below.

[0469] Table 21

[0470]

[0471] Example 11: Antibody diversity and binding affinity distribution in hVH / hcVL mice

[0472] Antigens D and E are type I transmembrane receptor proteins. Antigens D and E are used for hVH, respectively. H / H / hcVL K / K Mice were immunized (IGKV3-11 / J1). Then used... Photofluidic systems are used to separate plasma cells capable of producing antigen-specific monoclonal antibodies.

[0473] RNA was extracted from plasma cells, reverse transcribed into cDNA, and sequenced. A total of 1166 antibody heavy chain variable region sequences were obtained from antigen D. A total of 1290 heavy chain variable region antibody sequences were obtained from antigen E. The human genotypes of these antibody heavy chain sequences were determined. Results are shown in... Figures 33A-33B In the middle. Among them, the V region genes of all antibodies involve five subgroups of VH1-VH5 (including IGHV1, IGHV2, IGHV3, IGHV4, and IGHV5; see Figures 33A-33B The X-axis is shown in the diagram. The D region genes involve six subgroups of DH1-DH6 (including IGHD1, IGHD2, IGHD3, IGHD4, IGHD5, and IGHD6; see...). Figures 33A-33B (The left Y-axis is shown in the diagram). The J region genes involve six subgroups of JH1-JH6 (including IGHJ1, IGHJ2, IGHJ3, IGHJ4, IGHJ5, and IGHJ6; see...). Figures 33A-33B (The right Y-axis is shown in the diagram). The results indicate that the V, D, and J diversity of antibody heavy chains generated from anti-antigen D and anti-antigen E is high. This suggests that antibody heavy chain diversity is not affected in humanized common light mice.

[0474] The affinity of these antibodies was then determined using Biacore. The association rate (kon) and dissociation rate (koff) were obtained by fitting the data to a 1:1 Langmuir binding model (Karlsson, R. Roos, H. Fagerstam, L. Petersson, B., 1994. Methods Enzymology 6.99-110). The affinity (KD = koff / kon) was derived from the quotient of the kinetic rate constant. Analysis showed that KD was less than 1 × 10⁻⁶. -8 Antibodies against antigen M. These antibodies comprise 805 human common light chain antibodies against antigen D and 1026 human common light chain antibodies against antigen E. Antibody binding affinity (KD), kon, and koff values ​​are provided and ranked based on KD. Statistical analysis was performed. The distributions of KD, kon, and koff are shown in Figures 34-35.

[0475] Figures 34A-34B show the Kon and Koff rate distributions of antibodies against antigen D. Figures 34C-34D show the Kon and Koff rate distributions of antibodies against antigen E. Figure 35 shows the antibody binding affinity distribution, indicating that the Kon rate of these antibodies is mainly concentrated in the 1×10-1 range. 5 / Ms and 1×10 6 Between / Ms, koff is mainly concentrated at 1×10 -2 / S and 1×10 -3 The binding affinity (KD) is mainly concentrated between 0.10 nM and 100.00 nM, and these results are consistent with antibodies derived from natural immune responses. The data indicate that hVH... H / H / hcVL K / K Mice can produce antibodies with high affinity for a variety of antigens.

[0476] Example 12: hVH H / H / hcVL K / + Germ use analysis in mice

[0477] Select the homozygous humanized heavy chain immunoglobulin locus and the heterozygous humanized common light chain immunoglobulin locus (humanized VH). H / H / cVL K / + Mice, or denoted as hVH H / H / hcVL K / + Transgenic mice (of the mouse species) were used for pedigree analysis. hVH H / H / hcVL K / + Mice possessed rearranged human IGKV3-11 / J1 sequences. RNA was extracted from mouse spleen cells prior to antigen immunization. The extracted RNA was reverse transcribed, and the variable region of the immunoglobulin heavy chain was amplified by PCR. More specifically, PCR amplification was performed using an upstream primer (i.e., a cDNA terminus (RACE) primer at the 5' end) and a downstream primer targeting the region of the IgM-encoding gene. The amplified PCR products were purified, and non-immunized hVH was identified by next-generation sequencing (NGS). H / H / hcVL K / + Mouse pedigree usage. A total of 131,847 valid reads were obtained.

[0478] Analysis of non-immunized hVH H / H / hcVL K / + The use of heavy chain IGHV, IGHD, and IGHJ in mice. Results are shown in Figures 26A-26D Transcripts of 46 IGHV genes (including 2 pseudogenes) were detected. Additionally, transcripts of 25 IGHD genes and 6 IGHJ genes were detected. For example, as... Figure 26DAs shown, IGHJ3, IGHJ4, IGHJ5, and IGHJ6 in non-immunized hVH H / H / hcVL K / + It is frequently used in mice, while IGHJ1 and IGHJ2 are used less frequently. The usage pattern of the described IGHJ strains is consistent with the reported use of human IGHJ strains in humans.

[0479] Homozygous, non-immunized hVH was detected H / H / hcVL K / K The use of heavy chain IGHV and IGHD in mice. A total of 123,188 valid readings were obtained. Results are shown in... Figure 26E-26G Transcripts of 46 IGHV genes (including 2 pseudogenes: IGHV1-NL1 and IGHV3-38-3) were detected. The results were similar to those in heterozygous mice.

[0480] Table 22

[0481]

[0482] The heavy chain CDR3 length distribution is derived from non-immunized hVH H / H / hcVL K / + The immune lineage of spleen cells from mice (n=1) was determined by NGS sequencing. Figure 27A As shown, the median length of CDR3 is approximately 13-15 amino acids. Homozygous, non-immunized hVH H / H / hcVL K / K Results in mice as follows Figure 27B As shown in the figure. The results are also consistent with the median length of human heavy chain CDR3 in the human immune system.

[0483] The amino acid types at each position of the heavy chain CDR3 (HCDR3) were also analyzed. Figures 28A-28C (28D). These patterns are similar to the amino acid composition of human HCDR3.

[0484] Cysteine ​​residues can form disulfide bonds. Human HCDR3 may contain one or two cysteine ​​residues, while mouse HCDR3 usually does not contain cysteine. Figure 29 The results showed that hVH contains cysteine ​​residues. H / H / hcVL K / + The frequency of HCDR3 in mice was observed, and this frequency increased with increasing HCDR3 length. This result is consistent with the diversity of HCDR3 in human peripheral blood mononuclear cells (PBMCs). The results indicate that VDJ recombinant functions normally in hVH / hcVL mice.

[0485] Example 13: hVH H / H / hcVLK / + Somatic cell hypervariation analysis in mice

[0486] Select hVH of rearranged human IGKV3-11 / J1 sequence H / H / hcVL K / + Somatic cell hypervariable analysis was performed on mice. RNA was extracted from mouse spleen cells prior to antigen immunization. The extracted RNA was reverse transcribed into cDNA, and the rearranged human IGKV3-11 / J1 region was amplified by PCR using primers targeting human IGKV3-11 and IGJ1. The amplified PCR products were subjected to next-generation sequencing (NGS). 48,326 valid reads were obtained and analyzed using the IMGT / HighV-QUEST tool. Figures 30A-30B As shown, the results indicate that somatic hypermutation can occur in rearranged human light chain regions, but most somatic hypermutations are limited to changes in one or two amino acids. Homozygous, non-immune hVH H / H / hcVL K / K Results in mice as follows Figure 30C As shown. 48,541 valid reads were obtained and analyzed using the IMGT / HighV-QUEST tool. Similar to the results in heterozygous mice, most somatic mutations were limited to changes of only 1-2 nucleotides, and therefore only 1-2 amino acids. This indicates that in hVH... H / H / hcVL K / K In mice, somatic cell hypervariability is relatively low, and the variation is approximately 1-2 nucleotides (or amino acids).

[0487] Other implementation plans

[0488] It should be understood that although the invention has been described in conjunction with specific embodiments, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. SEQUENCE LISTING <110> Biocytok (Beijing) Pharmaceutical Technology Co., Ltd. <120> Genetically modified non-human animals possessing a shared light chain immunoglobulin locus <130> IDC220393 <150> PCT / CN2020 / 094000 <151> 2020-06-02 <150> PCT / CN2021 / 085839 <151> 2021-04-07 <160> 41 <170> PatentIn version 3.5 <210> 1 <211> 477 <212> DNA <213> Artificial Sequence <220> <223> IGKV1-39 <400> 1 atggacatga gggtccccgc tcagctcctg gggctcctgc tactctggct ccgaggtaag 60 gatggagaac actaggaatt tactcagcca gtgtgctcag tactgactgg aacttcaggg 120 aagttctctg ataacatgat taatagtaag aatatttgtt tttatgtttc caatctcagg 180 tgccagatgt gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga 240 cagagtcacc atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca 300 gcagaaacca gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg 360 ggtcccatca aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag 420 tctgcaacct gaagattttg caacttacta ctgtcaacag agttacagta cccctcc 477 <210> 2 <211> 516 <212> DNA <213> Artificial Sequence <220> <223> IGKV3-11 <400> 2 atggaagccc cagctcagct tctcttctc ctgctactct ggctcccagg tgaggggaac 60 atgaggtggt tttgcacatt agtgaaaact cttgccacct ctgctcagca agaaataataa 120 ttaaaattca aagtatatca acaattttgg ctctactcaa agacagttgg tttgatcttg 180 attacatgag tgcatttctg ttttatttcc aatttcagat accaccggag aaattgtgtt 240 gacacagtct ccagccaccc tgtctttgtc tccaggggaa agagccaccc tctcctgcag 300 ggccagtcag agtgttagca gctacttagc ctggtaccaa cagaaacctg gccaggctcc 360 caggctcctc atctatgatg catccaacag ggccactggc atcccagcca ggttcagtgg 420 cagtgggtct gggacagact tcactctcac catcagcagc ctagagcctg aagattttgc 480 agtttattac tgtcagcagc gtagcaactg gcctcc 516 <210> 3 <211> 537 <212> DNA <213> Artificial Sequence <220> <223> IGKV3-20 <400> 3 atggaaaccc cagcgcagct tctcttctc ctgctactct ggctcccagg tgaggggaac 60 atgggatggt tttgcatgtc agtgaaaacc ctctcaagtc ctgttacctg gcaactctgc 120 tcagtcaata caataattaa agctcaatat aaagcaataa ttctggctct tctgggaaga 180 caatgggttt gatttagatt acatgggtga cttttctgtt ttatttccaa tctcagatac 240 caccggagaa attgtgttga cgcagtctcc aggcaccctg tctttgtctc caggggaaag 300 agccaccctc tcctgcaggg ccagtcagag tgttagcagc agctacttag cctggtacca 360 gcagaaacct ggccaggctc ccaggctcct catctatggt gcatccagca gggccactgg 420 catcccagac aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag 480 actggagcct gaagattttg cagtgtatta ctgtcagcag tatggtagct cacctcc 537 <210> 4 <211> 38 <212> DNA <213> Artificial Sequence <220> <223> IGKJ1 <400> 4 gtggacgttc ggccaaggga ccaaggtgga aatcaaac 38 <210> 5 <211> 38 <212> DNA <213> Artificial Sequence <220> <223> IGKJ4 <400> 5 gctcactttc ggcggaggga ccaaggtgga gatcaaac 38 <210> 6 <211> 1189 <212> DNA <213> Mus musculus <400> 6 gtaagtacac ttttctcatc tttttttatg tgtaagacac aggttttcat gttaggagtt 60 aaagtcagtt cagaaaatct tgagaaaatg gagagggctc attatcagtt gacgtggcat 120 acagtgtcag atttctgtt tatcaagcta gtgagattag gggcaaaaag aggctttagt 180 tgagaggaaa gtaattaata ctatggtcac catccaagag attggatcgg agaataagca 240 tgagtagtta ttgagatctg ggtctgactg caggtagcgt ggtcttctag acgtttaagt 300 gggagatttg gaggggatga ggaatgaagg aacttcagga tagaaaaggg ctgaagtcaa 360 gttcagctcc taaaatggat gtgggagcaa actttgaaga taaactgaat gacccagagg 420 atgaaacagc gcagatcaaa gaggggcctg gagctctgag aagagaagga gactcatccg 480 tgttgagttt ccacaagtac tgtcttgagt tttgcaataa aagtgggata gcagagttga 540 gtgagccgta ggctgagttc tctcttttgt ctcctaagtt tttatgacta caaaaatcag 600 tagtatgtcc tgaaataatc attaagctgt ttgaaagtat gactgcttgc catgtagata 660 ccatggcttg ctgaataatc agaagaggtg tgactcttat tctaaaattt gtcacaaaat 720 gtcaaaatga gagactctgt aggaacgagt ccttgacaga cagctcaagg ggtttttttc 780 ctttgtctca tttctacatg aaagtaaatt tgaaatgatc ttttttatta taagagtaga 840 aatacagttg ggtttgaact atatgtttta atggccacgg ttttgtaaga catttggtcc 900 tttgttttcc cagttattac tcgattgtaa ttttatatcg ccagcaatgg actgaaacgg 960 tccgcaacct cttctttaca actgggtgac ctcgcggctg tgccagccat ttggcgttca 1020 ccctgccgct aagggccatg tgaacccccg cggtagcatc cttgctccg cgtggaccac 1080 tttcctgagg cacagtgata ggaacagagc cactaatctg aagagaacag agatgtgaca 1140 gactacacta atgtgagaaa aacaaggaaa gggtgactta ttggagatt 1189 <210> 7 <211> 500 <212> DNA <213> Homo sapiens <400> 7 gtaagtaatt tttcactatt gtcttctgaa atttgggtct gatggccagt attgactttt 60 agaggcttaa ataggagttt ggtaaagatt ggtaaatgag ggcatttaag atttgccatg 120 ggttgcaaaa gttaaactca gcttcaaaaa tggatttgga gaaaaaaga ttaaattgct 180 ctaaactgaa tgacacaaag taaaaaaaaa aagtgtaact aaaaaggaac ccttgtattt 240 ctaaggagca aaagtaaatt tatttttgtt cactcttgcc aaatattgta ttggttgttg 300 ctgattatgc atgatacaga aaagtggaaa aatacatttt ttagtctttc tcccttttgt 360 ttgataaatt attttgtcag acaacaataa aaatcaatag cacgccctaa gaaaaatcag 420 ggaaaagtga agtgtaccta tttgctatgt agaagaggca gcttacttga aaatcagcag 480 caatgttgtt tttagagtct 500 <210> 8 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 8 tcacacacta cagcttccaca cacaa 25 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 9 tgggcgcgcc agactctaaa 20 <210> 10 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 10 tgggtctgat ggccagtatt gact 24 <210> 11 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 11 ggcctggaaa actcagctat ccttt 25 <210> 12 <211> 31 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 12 gccaaggaat ttaaaagggg attgaaagca a 31 <210> 13 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 13 agggagggaa tggaatgagg gtgat 25 <210> 14 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 14 ccatgtgacc cattcgagtg tcctg 25 <210> 15 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 15 cttaccattt gcggtgcctg gtttc 25 <210> 16 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 16 tcacacacta cagcttccac cacaa 25 <210> 17 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 17 tgggcgcgcc agactctaaa 20 <210> 18 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 18 tgggtctgat ggccagtatt gact 24 <210> 19 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 19 ggcctggaaa actcagctat ccttt 25 <210> 20 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 20 tcacacacta cagcttccac cacaa 25 <210> 21 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 21 tgggcgcgcc agactctaaa 20 <210> 22 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 22 tgggtctgat ggccagtatt gact 24 <210> 23 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 23 ggcctggaaa actcagctat ccttt 25 <210> 24 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 24 agacttgatg gtgtggagtg gggta 25 <210> 25 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 25 tgggccctgt actttgcttg aacat 25 <210> 26 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 26 tgatgggtca accatgttcc tgtgg 25 <210> 27 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 27 tcagccattg cttctgcttt ctcct 25 <210> 28 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 28 gaaaagtggc tttgatggtg caggg 25 <210> 29 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 29 tgcccatttt tctgcccttg ggtat 25 <210> 30 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 30 aggcattcct tatgccagtc agcat 25 <210> 31 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 31 tttcccatgt cctgctgctt tcctt 25 <210> 32 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 32 catttaggga gctgactggg cacaa 25 <210> 33 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 33 tctgggtcct aactgagcag ctctt 25 <210> 34 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 34 ctaacactca ttcctgttga agctcttgac 30 <210> 35 <211> 3012 <212> DNA <213> Artificial Sequence <220> <223> Rearranged human IGKV1-39+J4 nucleic acid sequence <400> 35 gcaggcagca tatttataat gcacagtaaa cactaggagg aaacaaggca gtgagagagg 60 aaagagagca gcgataccga aaatgtcctc agcgagaagc taccacagag gatgaatgga 120 gatcaagccc acgtggaaac atgggaaaat gtctcagtat ttttccacct aagaagggag 180 ggagatgggg tatgtataca cctccctgtc ctcactgatt gagggctttc cgagaggatg 240 ctcattccag gtgctgtgat aggccatgtg tacaggcagg gctgccttct ccagcttcag 300 atagagcagt gaggaaaaga tatggccatg gggggtcagc agaagtacag caaagggaaa 360 agggaaaggg tagcaagagt gacaactata ttcacccccc ccacacacac acacacacac 420 acgaaattgt gtattgcaat ccagaactgc ttctctctga acctaaatct tagcaagcag 480 tttaccagta actgcccttg aaattcaggc ccctggaaag gagcaggggg ttgtgtacag 540 gctataccac agcagtctgc ccacccttag tgatgcatga gtaatgctcc ctggactccc 600 caggttctag tcttctcatg tcgatgtagt tgattccact tcccttgctg cacaaccagg 660 ctgggatgcc tgggcagagg cagacatgtg aggtataggg gttcaaatct gtttccaagt 720 tttatccagc ttcaaagcat ttctccgtgt acatgagcgg tggcttgaca ggagatggag 780 actctctttc ctggatgtga ggcaaggagg caggcgtctg agtcaggatg atgtccctac 840 tcactgctaa agagaaaagt ggctttgatg gtgcagggca gggaaatgca ctgagtggtc 900 gccaccctca cagaagagaa agtgttcact gacctggcct ttccccaggg cctctccctc 960 ccattgcttt ccagaaagcc atgatttttg agagccacac ctgaacactc acaaacatta 1020 tggtgggaaa agcagatcag agcattaggc aagttgcatt accttggcct tctctccttg 1080 gagacaattg atgtggggtt ctagattgac ccagagtttc aagtttatcc tgattcaggc 1140 ttcacagct ggaggagaa acagagatgt tttttgaagt aaacagatct agcattacta 1200 atcaaccctt catactgatg acctatggga ataataccc aagggcagaa aaatgggcag 1260 aaagggga gccccaacc agacgaagc tgctgccat tgagaccctg gttattacag 1320 agacctatag ctctggataa tggagatct atgagtggca caggcgctga ggaatcacag 1380 catcattatc gtgcatctgc agggaattgc ttgtaataat actgtaatt acaaatgttt 1440 aaggtcacta caatacttt ggagtgtatt aaatatgctt ctgataaga ctgttttttct 1500 cacatgaaac aatgggaacc atgtgacaat cacagaggtg ttgttactat agcaaaggg 1560 attgttactc tccacatccc tttaagtaac ttgaagcct gatagaccca ccctctaaga 1620 cttcattaga cattccctac gatggttat actctcctgt atactcccaa tacaactcta 1680 aaatatatta ttccatatag tccttaggtt tgtattaaag tttgacttt ttccttcaaa 1740 atatctcttg tcacaacagc ggctctagag agaaatacat tccctccagg caaatctatg 1800 ctgcgctggt ctgacctggg accctgggga cattgcccct gtgctgagtt actaagatga 1860 gccagccctg cagctgtgct cagcctgccc catgccctgc tgattgattt gcatgttcca 1920 gagcacagcc ccctgccctg aagacttttt tatgggctgg tcgcaccctg tgcaggagtc 1980 agtctcagtc aggacacagc atggacatga gggtccccgc tcagctcctg gggctcctgc 2040 tactctggct ccgaggtaag gatggagaac actaggaatt tactcagcca gtgtgctcag 2100 tactgactgg aacttcaggg aagttctctg ataacatgat taatagtaag aatatttgtt 2160 tttatgtttc caatctcagg tgccagatgt gacatccaga tgacccagtc tccatcctcc 2220 ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc gggcaagtca gagcattagc 2280 agctatttaa attggtatca gcagaaacca gggaaagccc ctaagctcct gatctatgct 2340 gcatccagtt tgcaaagtgg ggtcccatca aggttcagtg gcagtggatc tgggacagat 2400 ttcactctca ccatcagcag tctgcaacct gaagattttg caacttacta ctgtcaacag 2460 agttacagta cccctctcac ttcggcgga gggaccaagg tggagatcaa acgtaagtaa 2520 ttttcacta ttgtcttctg aaatttgggt ctgatggcca gtattgactt ttagaggctt 2580 aaataggagt ttggtaaaga ttggtaaatg agggcattta agatttgcca tgggttgcaa 2640 aagttaaact cagcttcaaa aatggatttg gagaaaaaaa gattaaattg ctctaaactg 2700 aatgacacaa agtaaaaaaa aaaagtgtaa ctaaaaagga acccttgtat ttctaaggag 2760 caaaagtaaa tttatttttg ttcactcttg ccaaatattg tattggttgt tgctgattat 2820 gcatgataca gaaaagtgga aaaatacatt ttttagtctt tctcccttt gtttgataaa 2880 ttattttgtc agacaacaat aaaaatcaat agcacgccct aagaaaaatc agggaaaagt 2940 gaagtgtacc tatttgctat gtagaagagg cagcttactt gaaaatcagc agcaatgttg 3000 ttttagagt ct 3012 <210> 36 <211> 3051 <212> DNA <213> Artificial Sequence <220> <223> Rearranged human IGKV3-11+J1 nucleic acid sequence <400> 36 caggagtgag cctggtttga tgcctctctc cccaacacga tagaagtgtg gcacaaatct 60 ttgaaaaatt cagtttcccc gtggcaacaa caactacctg ggactgaaaa cttcttccct 120 cgctctagtc cttcttcta cacccacttc cacctcatct gtgactcata caatacttgt 180 caggaaagat tctggaaaaa gcaaagagac ttccttagag gtgtcagaga ttcctgtacc 240 agcatctgtc catctctaga gggggttgtg agtatgagga agagcagagc ttgtcaatct 300 tctacttgct ttcactccca ctgtatttcc taacaacagc aaccagagca acagccatat 360 catcacagga cgaacctctc ctacttccaa ggcttttatt tcagtaaatc tgctctacct 420 ctatctcagg cagctagaag ttttgatact catacaaata ctactgcagc tttctgttca 480 taattggaaa agtagacaag actcagtgta atgcaggcat tccttatgcc agtcagcatt 540 cagtttttgg atcatcattg cacacatata cccaccatgt gtctaatata tatgtaaaaa 600 tccatgaagc aagagtcata atagctagca tttgatattg tattgtattt tcctcttata 660 tcatcttctc cttttcgtcc ttaaaaaaaa tctgttcaag tcagtctaaa ttaattattg 720 gatgataagt agataaaatc ttttattga taacacattg acccaatgaa tatgttttctt 780 tgcaagacat agtcctcact tccaagata caagcctgac aaaattatac tggagcaagt 840 ccacaagtaa tgatggtagc tttccttat tgtcagtcct ggggcaaaa taagacaaaa 900 gataaaagg tagataag attagtaag aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa''aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa hasaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa'’aaaaaaaaaaackaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa thata' thataaach that's 960 tttcatagga taacattttg ataatggatg atgagaatta atgcgttaga cagagatggg 1020 cgggaatgat tgaggtctg agcatttag cacagattaa gaccaatca taggatttt 1080 aagagttgtg tacagttagt gagaaaaag ccctagaatt taatttgact gttgataaaa 1140 cattcttgga ttagattgaa gactctttc tgtgccaagt aagtatattt atgataatga 1200 tgatgactgt agtgctaaat atttaatcaa taaaaaaaaaattgcc gcatacataa 1260 tgtcctgagt actactgtaa atgttttac ttattttt taaactgtct acagcactgt 1320 aaggtaggca ccagtattgt cacagttaca cagatatgga aactgagaca cagggaagtt 1380 aagttagttg gtcaatttca agcaatcggc aagccatgga gcatctatgt cagggctgcc 1440 aggacatgtg actgtaaca gaagttttaa ctttttaact caaagggt atgtgtctgg 1500 gttaatggaa agtttcagga ccctcagaa acactacta caagcaatg aaggtgtat 1560 ctggaagatt aagttctaac agactcctca ttccatcga tccaataatg cacttagg 1620 gatgactggg catattgagg ataggagag agaatgaaaacagcctt ttatattgtt 1680 cttaacaggc tgtgccaaa catcatctgg gtgaatttag gtgattgagg agaagaaaga 1740 cataggaatg aaattctctg agcacaaggg agaagttcta cactcagact gagcacag 1800 acttttctgg cctgacaacc agggtggcgc aggatgctca gtgcagagag gagaagcag 1860 gtggtctctg cagctggaag ctcagctccc acccagctgc ttgcatgtc cctcccagct 1920 gccctacctt ccagagccca tatcaatgcc tgtgtcagag ccctggggag gaactgctca 1980 gttaggaccc agagggaacc atggaagccc cagctcagct tctctcctc ctgctactct 2040 ggctcccagg tgagggac atgaggtggt ttgcacatt agtgaaaact cttgccacct 2100 ctgctcagca agaatataa ttaaattca aagtatatca acaatttgg ctctactcaa 2160 agacagttgg tttgatcttg attacatgag tgcatttctg ttttatttcc aatttcagat 2220 accaccggag aaattgtgtt gacacagtct ccagccaccc tgtctttgtc tccaggggaa 2280 agagccaccc tctcctgcag ggccagtcag agtgttagca gctacttagc ctggtaccaa 2340 cagaaacctg gccaggctcc caggctcctc atctatgatg catccaacag ggccactggc 2400 atcccagcca ggttcagtgg cagtgggtct gggacagact tcactctcac catcagcagc 2460 ctagagcctg aagattttgc agtttattac tgtcagcagc gtagcaactg gcctccgacg 2520 ttcggccaag ggaccaaggt ggaaatcaaa cgtaagtaat ttttcactat tgtcttctga 2580 aatttgggtc tgatggccag tattgacttt tagaggctta aataggagtt tggtaaagat 2640 tggtaaatga gggcatttaa gatttgccat gggttgcaaa agttaaactc agcttcaaaa 2700 atggatttgg agaaaaaaag attaaattgc tctaaactga atgacacaaa gtaaaaaaaa 2760 aaagtgtaac taaaaaggaa cccttgtatt tctaaggagc aaaagtaaat ttatttttgt 2820 tcactcttgc caaatattgt attggttgtt gctgattatg catgatacag aaaagtggaa 2880 aaatacattt tttagtcttt ctccctttg tttgataaat tattttgtca gacaacaata 2940 aaaatcaata gcacgcccta agaaaaatca gggaaaagtg aagtgtacct atttgctatg 3000 tagaagaggc agcttacttg aaaatcagca gcaatgttgt ttttagagtc t 3051 <210> 37 <211> 3072 <212> DNA <213> Artificial Sequence <220> <223> Rearranged human IGK V3-20+J1 nucleic acid sequence <400> 37 agccagtgga tgactatttt ctttcctgag actgataatg gtcattccac ccaatggtcc 60 aaactacatg cagtggtaat ggtcatgcag gcctttctgc cacctcttgc tatatttttta 120 ccaactcatg ggccactgcc aacagtctag ctatctgatc aggaaatag caaccgagtg 180 actggactat taaagcatcc cctctgtgga gaaaaggact atggcaacag cttgccacct 240 ataagagaca aatatgtcac tcagctggat gctgggtcta ccatgaccac ccttgagatg 300 aacttatgcc atgtttttgg atgcccactg agactttgct ttgaccaagg aaagttcttt 360 actgcccaaa tgacgtcaat ggacacactc tcatgggaca tgatggattt tccatacacc 420 ttgttatcca aaggccaatg gatctattta atgctagaac agctgactca cacggcaact gaagagtgta catcagggca acctgctagt aggtggtac cccatctgac tacagcaatt ggacattaaa cactgcactg cagagcaagg gaaagacggc acggaggtgc aggttgaaaa acactgagtt gagtgagga gagttgggc aaggccagtt tcctgataga gctgccactg 660 tgaatccca aactcagtgt ttccaatcat ttttttcctt ttatagtgat gttcttgggg 720 gtgttgcagt ttaggccacc atgataaccc agacaggcct cctaactcta attggatgga 780 atgattcccc tgggtgcctt ctatgggttc you are your mother gggtgttaat ttccttctgc tggtaggagg gtcatctgat tcctccatta gggtggatga cgttatcaga 900 catgtcaatt ttctacagta cttgacctgc cttctagaac tggacaaccg agggtgaaag gactggatca agcaacaatg gcaatgggtg cccaaagagg tagtagtctc agaacaggga gagacagact gagtccctcc actaactcag cccaacacct gtggatgagt aggggatgcc tgagatcctg gggtggatgg gaggtggggc actgatctgt caatctgctt tttcttcaag 1140 gatcaggcag cagagaccca gagcttcat gtctttgtaa ggctcttcca agccaacaca gataatttga caaaacactg tatctgcatc ccagacctca ccctgtcaca gactgaagtg gttgtttcat cctactaagg gtaaactata ccgctatac agaataaaaa gactggatag tttagaggat cacccaagaa atagttcttt gcctgcatgg acaaaaccat cttctgtctt tagggaaatg gtatcactac cctgaggatt tggagcccag gtctcactta tctgtgcagt tgtgaaagtc ctcacaccca cagtgctgag gttaattgaa tgttactctt ttaatttctg 1560. 1560. 1560. 1560. 1560. 1560. 1560. 1560. 1560. 1560 atccggaaga taaagttgta atagactctt cctttcaacc tgatccatca tgcatttagg gagctgactg ggcacaagtt ggagcagaaa gagaaaaatg aaaccacagc cttctatttt gtttctaaca gacttgtacc aaacattctg tggctcaatc taggtgatgg tgagacaaga ggacacaggg gttaattct gtggccgcag gggagaagtt ctaccctcag actgagccaa cggccttttc tggcctgatc acctgggcat gggctgctga gagcagaaag gggaggcaga 1860 ttgtctctgc agctgcaagc ccagcacccg ccccagctgc tttgcatgtc cctcccagcc 1920 gccctgcagt ccagagccca tatcaatgcc tgggtcagag ctctggagaa gagctgctca 1980 gttaggaccc agagggaacc atggaaaccc cagcgcagct tctcttcctc ctgctactct 2040 ggctcccagg tgaggggaac atgggatggt tttgcatgtc agtgaaaacc ctctcaagtc 2100 ctgttacctg gcaactctgc tcagtcaata caataattaa agctcaatat aaagcaataa 2160 ttctggctct tctgggaaga caatgggttt gatttagatt acatgggtga cttttctgtt 2220 ttatttccaa tctcagatac caccggagaa attgtgttga cgcagtctcc aggcaccctg 2280 tctttgtctc caggggaaag agccaccctc tcctgcaggg ccagtcagag tgttagcagc 2340 agctacttag cctggtacca gcagaaacct ggccaggctc ccaggctcct catctatggt 2400 gcatccagca gggccactgg catcccagac aggttcagtg gcagtgggtc tgggacagac 2460 ttcactctca ccatcagcag actggagcct gaagattttg cagtgtatta ctgtcagcag 2520 tatggtagct caccttggac gttcggccaa gggaccaagg tggaaatcaa acgtaagtaa 2580 ttttcacta ttgtcttctg aaatttgggt ctgatggcca gtattgactt ttagaggctt 2640 aaataggagt ttggtaaaga ttggtaaatg agggcattta agatttgcca tgggttgcaa 2700 aagttaaact cagcttcaaa aatggatttg gagaaaaaaa gattaaattg ctctaaactg 2760 aatgacacaa agtaaaaaaa aaaagtgtaa ctaaaaagga acccttgtat ttctaaggag 2820 caaaagtaaa tttatttttg ttcactcttg ccaaatattg tattggttgt tgctgattat 2880 gcatgataca gaaaagtgga aaaatacatt ttttagtctt tctcccttt gtttgataaa 2940 ttattttgtc agacaacaat aaaaatcaat agcacgccct aagaaaaatc agggaaaagt 3000 gaagtgtacc tatttgctat gtagaagagg cagcttactt gaaaatcagc agcaatgttg 3060 ttttagagt ct 3072 <210> 38 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> common light chain VL encoded by human IGKV1-39 / IGKJ4 <400> 38 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 39 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> common light chain VL encoded by human IGKV3-11 / IGKJ1 <400> 39 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 40 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> common light chain VL encoded by human IGKV3-20 / IGKJ1 <400> 40 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 41 <211> 107 <212> PRT <213> Mus musculus <400> 41 Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu 1 5 10 15 Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe 20 25 30 Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg 35 40 45 Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu 65 70 75 80 Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser 85 90 95 Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys 100 105

Claims

1. A method for producing genetically modified non-human animals, wherein, The genetically modified non-human animal contains an exogenous kappa light chain variable region gene sequence at the endogenous kappa light chain immunoglobulin gene locus, wherein the exogenous kappa light chain variable region gene sequence includes a human IGKV gene and a human IGKJ gene, wherein the human IGKV gene and the human IGKJ gene are operatively linked to an endogenous light chain constant domain gene. (1) The human IGKV gene is IGKV1-39, and the human IGKJ gene is IGKJ4; or (2) The human IGKV gene is IGKV3-11, and the human IGKJ gene is IGKJ1; The animal in question is a mouse, and it contains a disruption of the endogenous kappa light chain immunoglobulin gene locus.

2. The method according to claim 1, wherein the exogenous kappa light chain variable region gene sequence further comprises a human IGKJ 3'-UTR sequence.

3. The method according to claim 1 or 2, wherein the exogenous kappa light chain variable region gene in one or more cells of the animal undergoes or does not undergo somatic hypermutation.

4. The method of claim 3, wherein the somatic hypermutation can result in a change of up to one or two amino acids in the light chain variable region of one or more cells of the animal.

5. The method of claim 1 or 2, wherein the animal further comprises a promoter sequence operatively linked to the human IGKV gene, wherein the promoter sequence is within 2500 bp or 3000 bp of the human IGKV gene.

6. The method according to claim 5, wherein the promoter is the IGKV3-11 promoter or the IGKV1-39 promoter.

7. The method of claim 1, wherein the disruption in the endogenous light chain immunoglobulin locus of the animal comprises a deletion of the sequence from mouse IGKV2-137 to mouse IGKJ5.

8. The method according to claim 1 or 2, wherein the animal contains endogenous IGKC.

9. The method of claim 8, wherein the animal further comprises a κ intronic enhancer and / or a κ3' enhancer located at the 5' end of the endogenous IGKC.

10. The method according to claim 1 or 2, wherein the exogenous kappa light chain variable region is a rearranged sequence.

11. The method according to claim 1 or 2, wherein the animal is homozygous relative to the light chain immunoglobulin locus.

12. The method according to claim 1 or 2, wherein the animal is heterozygous relative to the light chain immunoglobulin locus.

13. The method of claim 1, wherein the animal comprises an unmodified human sequence derived from the human heavy chain immunoglobulin locus from human IGHV (III)-82 to human IGHJ6, the animal comprising disruption of the endogenous heavy chain immunoglobulin locus.

14. The method of claim 13, wherein the disruption of the endogenous heavy chain immunoglobulin locus in the animal comprises the deletion of a sequence from mouse IGHV1-85 to mouse IGHJ4.

15. The method of claim 13, wherein the animal comprises one or more endogenous IGHM, IGHδ, IGHG3, IGHG1, IGHG2b, IGHG2a, IGHE, and IGHA genes.

16. The method of claim 13, wherein the animal is homozygous relative to the heavy chain immunoglobulin locus.

17. The method of claim 13, wherein the animal is heterozygous relative to the heavy chain immunoglobulin locus.

18. The method according to any one of claims 1-2, 13-17, wherein the animal lacks an endogenous immunoglobulin heavy chain variable region locus capable of rearranging and forming a nucleic acid sequence encoding an endogenous heavy chain variable domain.

19. The method according to any one of claims 1-2, 13-17, wherein the animal lacks an endogenous immunoglobulin light chain variable region locus capable of rearranging and forming a nucleic acid sequence encoding an endogenous light chain variable domain.

20. The method according to any one of claims 1-2, 13-17, wherein the animal can produce humanized antibodies.

21. The method of claim 20, wherein the antibody comprises a light chain variable region encoded by the IGKV gene and the IGKJ gene.

22. A method for preparing a chimeric antibody that specifically binds to an antigen, the method comprising: Animals produced by the method according to any one of claims 1-21 are exposed to the antigen; Hybridomas are generated from cells collected from the animals; and Collect the chimeric antibodies produced by the hybridoma.

23. The method of claim 22, wherein the method further comprises sequencing the genome of the hybridoma.

24. A method for preparing an antibody that specifically binds to an antigen, the method comprising exposing an animal produced by the method according to any one of claims 1-21 to the antigen; Sequencing of nucleic acids encoding the variable regions of human heavy chain and human light chain immunoglobulins in cells, wherein the cells express chimeric antibodies that specifically bind to the antigens; and In the cell, the nucleic acid encoding the variable region of the human heavy chain immunoglobulin is operatively linked to the nucleic acid encoding the constant region of the human heavy chain immunoglobulin, and the nucleic acid encoding the variable region of the human light chain immunoglobulin is operatively linked to the nucleic acid encoding the constant region of the human light chain immunoglobulin.

25. A method for obtaining a nucleic acid encoding an antigen-binding domain that specifically binds to an antigen, the method comprising: Animals produced by the method according to any one of claims 1-21 are exposed to the antigen; as well as The nucleic acids encoding the variable regions of human heavy and light chain immunoglobulins in cells were sequenced, and the cells expressed chimeric antibodies that specifically bind to the antigen.

26. A method for obtaining a sample, the method comprising: Animals produced by the method according to any one of claims 1-21 are exposed to the antigen; and The sample is collected from the animal, wherein the sample is spleen tissue, spleen cells or B cells.

27. A method for preparing an antibody that specifically binds to a target protein, the method comprising: Animals produced by the method according to any one of claims 1-21 are exposed to the target protein, wherein the animals do not express endogenous proteins homologous to the target protein; as well as The nucleic acids encoding the variable regions of human heavy and light chain immunoglobulins in cells were sequenced, and the cells expressed antibodies that specifically bind to the target proteins.

28. The method of claim 27, wherein the gene encoding the endogenous protein is disrupted in the animal.

29. The method of claim 28, wherein the gene encoding the endogenous protein is knocked out.

30. The method according to any one of claims 27-29, wherein the endogenous protein is at least 80% identical to the target protein.

31. The method according to any one of claims 27-29, wherein the target protein is a human protein.

32. The method according to any one of claims 27-29, wherein the target protein is PD-1, CTLA-4, LAG-3, BTLA, PD-L1, CD27, CD28, CD47, CD137, CD154, TIGIT, TIM-3, GITR, SIRPa, or OX40.

Citation Information

Patent Citations

  • Novel method for establishing embryonic stem cells containing exogenous chromosome

    CN109837307A

  • Chimeric animal and method for constructing the same

    CN1200014A

  • Human artificial chromosome (HAC) vector

    CN1717483A

  • Isolation of a rearranged human immunoglobulin gene from a chimeric mouse and recombinant production of the encoded immunoglobulin

    US20090253902A1

  • Human artificial chromosome (HAC) vector

    US20120093785A1